

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

35 C13982

First Named Inventor or Application Identifier

Tetsuya Yano

Express Mail Label No.

USPTO
09/430029

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

2. ☒ Specification Total Pages **117**

3. ☒ Drawing(s) (35 USC 113) Total Sheets **36**

4. ☒ Oath or Declaration Total Pages **2**

- a. ☐ Newly executed (original or copy)
b. ☒ Unexecuted for information purposes
c. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]

☐ **DELETION OF INVENTOR(S)**
Signed Statement attached deleting
inventor(s) named in the prior application, see
37 CFR 1.63(d)(2) and 1.33(b)

5. ☐ Incorporation By Reference (useable if Box 4c is checked)
The entire disclosure of the prior application, from which a copy of
the oath or declaration is supplied under Box 4c, is considered as
being part of the disclosure of the accompanying application and is
hereby incorporated by reference therein

6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. ☐ Computer Readable Copy
b. ☒ Paper Copy (identical to computer copy)
c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application
Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other _____

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. ____/____

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

05514

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

Address

City

State

Zip Code

Country

Telephone

Fax

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1 16(c))	123-20 =	103	X \$ 18 00 =	\$1854 00
	INDEPENDENT CLAIMS (37 cfr 1 16(b))	11-3 =	8	X \$ 78 00 =	\$624 00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1 16(d))			\$260 00 =	\$260 00
				BASIC FEE (37 CFR 1 16(a))	\$760 00
			Total of above Calculations =		\$3498 00
	Reduction by 50% for filing by small entity (Note 37 CFR 1 9, 1 27, 1 28)				
	TOTAL =				\$3498 00

19. Small entity status


- a ☐ A Small entity statement is enclosed
- b ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired
- c ☐ Is no longer claimed

20. ☒ A check in the amount of \$ 3498 00 to cover the filing fee is enclosed

21. ☐ A check in the amount of \$ _____ to cover the recordal fee is enclosed

22. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No 06-1205

- a ☒ Fees required under 37 CFR 1 16
- b ☒ Fees required under 37 CFR 1 17
- c ☐ Fees required under 37 CFR 1 18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
NAME	Lawrence S. Perry Registration No. 31,865
SIGNATURE	
DATE	October 28, 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
: Examiner: Not Yet assigned
Tetsuya Yano, et al.)
: Group Art Unit: N/Y/A
Application No.: N/Y/A)
:
Filed: Currently herewith)
:
For: DNA FRAGMENT CARRYING)
TOLUENE MONOOXYGENASE :
GENE, RECOMBINANT)
PLASMID, TRANSFORMED :
MICROORGANISM, METHOD)
FOR DEGRADING :
CHLORINATED ALIPHATIC)
HYDROCARBON COMPOUNDS :
AND AROMATIC COMPOUNDS,)
AND METHOD FOR :
ENVIRONMENTAL)
REMEDICATION : October 28, 1999

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to action on the merits, please amend the
above-identified application as follows:

IN THE CLAIMS:

Please amend Claims 11 and 55 as follows:

Claim 11, line 3, change "6 to 9" to --6, 7 or 9--.

55. (Amended) A recombinant DNA comprising a vector, a promoter, a first DNA fragment being the DNA fragment of any one of claims 6 [to], 7 or 9, and a second DNA fragment [being the tomK DNA fragment of claim 10], said second DNA fragment comprising a region encoding a polypeptide TomK having an amino acid sequence of SEQ ID NO: 2, and a property to enhance the toluene monooxygenase activity of a protein comprised of at least TomL to TomP; or a region encoding a variant TomK in which the amino acid sequence of SEQ ID NO:2 is altered with the proviso that the property to enhance the toluene monooxygenase activity is not impaired,

wherein the first DNA fragment is functionally connected to the promoter to express an active toluene monooxygenase, and the second DNA fragment is functionally connected to the promoter to express a property to enhance the toluene monooxygenase activity.

REMARKS

Claims 11 and 55 have been amended to correct their dependency and conformity with accepted U.S. practice.

No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Attorney for Applicants

Registration No. 3865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

DNA FRAGMENT CARRYING TOLUENE MONOOXYGENASE GENE,
RECOMBINANT PLASMID, TRANSFORMED MICROORGANISM, METHOD
FOR DEGRADING CHLORINATED ALIPHATIC HYDROCARBON
COMPOUNDS AND AROMATIC COMPOUNDS, AND METHOD FOR
5 ENVIRONMENTAL REMEDIATION

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a novel DNA
10 fragment carrying a toluene monooxygenase gene, a novel
recombinant DNA containing the DNA fragment, a
transformant containing the recombinant DNA, and a
method for degrading chlorinated aliphatic hydrocarbon
compounds such as trichloroethylene (TCE) and
15 dichloroethylene (DCE) and aromatic compounds such as
toluene, benzene, phenol, and cresol. The present
invention also relates to a method for environmental
remediation useful for cleaning of aqueous media such
as wastewater and effluent containing at least either a
20 chlorinated aliphatic hydrocarbon compound or an
aromatic compound and air (gas phase) and soil polluted
with chlorinated aliphatic hydrocarbon compounds.

Related Background Art

Recently, it has become a serious problem the
25 environmental pollution with volatile organic
chlorinated compounds which are harmful to the
organisms and hardly degradable. Especially, the soil

in the industrial areas in Japan as well as abroad is considered to be contaminated with chlorinated aliphatic hydrocarbon compounds such as tetrachloroethylene (PCE), trichloroethylene (TCE), and dichloroethylene (DCE) and aromatic compounds such as toluene, benzene, phenol, and cresol. There have been a number of reports on actual detection of such pollutants through environmental surveys. It is supposed that these compounds remaining in soil dissolve in ground water via rainwater, and thereby spread over the surrounding areas. There is a strong suspicion that these compounds are carcinogens, and further, these are quite stable in the environment; therefore contamination of groundwater, which is used as a source of drinking water, has become a serious social problem. Therefore, cleaning of aqueous media such as contaminated groundwater and soil through removal and degradation of these compounds and accompanying cleaning of the surrounding gas phase are quite important in view of the environment protection. Technologies required for cleaning (for example, adsorption treatment using activated carbon, degradation treatment using light and heat) have been developed. Technologies presently available, however, are not always practical in terms of cost and operability. Recently, microbial degradation of chlorinated aliphatic hydrocarbon compounds such as TCE

that is stable in environment has been reported. The microbial degradation method have advantages such as: (1) degradation of chlorinated aliphatic hydrocarbon compounds into harmless substances by using appropriately selected microorganism; (2) no requirement for any special chemicals in principle; and (3) reduction of the labor and costs of maintenance.

The examples of microorganisms capable of degrading TCE are as follows:

Welchia alkenophila sero 5 (U.S. Patent No. 4877736, ATCC 53570, Welchia alkenophila sero 33 (U.S. Patent No. 4877736, ATCC 53571), Methylocystis sp. Strain M (Agric. Biol. Chem., 53, 2903 (1989), Biosci. Biotech. Bichem., 56, 486 (1992), ibid. 56, 736 (1992)), Methylosinus trichosporium OB3b (Am. Chem. Soc. Natl. meet. Div. Environ. Microbiol., 29, 365 (1989), Appl. Environ. Microbiol., 55, 3155 (1989), Appl. Biochem. Biotechnol. 28, 877 (1991), Japanese Patent Application Laid-Open No. 2-92274 specification, Japanese Patent Laid-Open Application No. 3-292970), Methylomonas sp. MM2 (Appl. Environ. Microbiol., 57, 236 (1991), Alcaligenes denitrificans ssp. Xylosoxidans JE75 (Arch. Microbiol., 154, 410 (1990), Alcaligenes eutrophus JMP134 (Appl. Environ. Microbiol., 56, 1179 (1990), Alcaligenes eutrophus FERM-13761 (Japanese Patent Laid-Open Application No. 7-123976), Pseudomonas

aeruginosa J1104 (Japanese Patent Application Laid-Open No. 7-236895), Mycobacterium vaccae JOB5 (J. Gen. Microbiol., 82, 163 (1974), Appl. Environ. Microbiol., 55, 2960 (1989), ATCC 29678), Pseudomonas putida BH (Gesuidou Kyokai-shi (Japan Sewage Works Association Journal), 24, 27 (1987)), Pseudomonas sp. strain G4 (Appl. Environ. Microbiol., 52, 383 (1968), *ibid.* 53, 949 (1987), *ibid.* 54, 951 (1988), *ibid.* 56, 279 (1990), *ibid.* 57, 193 (1991), U.S. Patent No. 4925802, ATCC 53617, this strain was first classified as Pseudomonas cepacia and then changed to Pseudomonas sp.), Pseudomonas mendocina KR-1 (Bio/Technol., 7, 282 (1989)), Pseudomonas putida F1 (Appl. Environ. Microbiol., 54, 1703 (1988), *ibid.* 54, 2578 (1988)), Pseudomonas fluorescens PFL12 (Appl. Environ. Microbiol., 54, 2578 (1988)), Pseudomonas putida KWI-9 (Japanese Patent Application Laid-Open No. 6-70753), Pseudomonas cepacia KK01 (Japanese Patent Application Laid-Open No. 6-22769), Nitrosomonas europaea (Appl. Environ. Microbio., 56, 1169 (1990), Lactobacillus vaginalis sp. nov (Int. J. Syst. Bacteriol., 39, 368 (1989), ATCC 49540), Nocardia corallina B-276 (Japanese Patent Application Laid-Open No. 8-70881, FERM BP-5124, ATCC 31338), and so on.

The problem in actually using these degrading microorganisms in environmental remediation treatment, however, resides in optimizing and maintaining

expression of their degradation activity for
chlorinated aliphatic hydrocarbon compounds such as
TCE. In an environmental remediation treatment which
utilizes phenol, toluene, methane, or the like as an
5 inducer, continuous supply of the inducer is
indispensable, since depletion of such inducers
directly results in stoppage of degradation of
chlorinated aliphatic hydrocarbon compounds. Presence
of such inducers, on the other hand, may inhibit the
10 efficient degradation of the target substance such as
TCE, since the affinity of the chlorinated aliphatic
hydrocarbon compounds such as TCE as a substrate is
considerably low in comparison with these inducers. In
addition, precise control of the inducer concentration
15 on the treatment spot is difficult.

Thus, use of an inducer is a large problem in
practical application of environmental remediation
treatment utilizing microorganisms.

In order to solve the problem, Nelson et al.
20 developed a method using tryptophan as an inducer for
degradation of volatile organic chlorinated compounds
(Japanese Patent Application Laid-Open No. 4-502277).
Tryptophan, however, is a very expensive substance, and
although tryptophane has no toxicity or risk as a
25 substance, it is not preferable to introduce excessive
carbon and nitrogen sources into environment since it
may induce eutrophication. In addition, the problem

that tryptophan serves as a competitive inhibitor in degradation of TCE still remains.

Shields et al. obtained a mutant strain of Pseudomonas cepacia G4 (changed to Pseudomonas sp. upon deposition to ATCC) by the transposon technique, which mutant strain does not require an inducer (in this case, phenol or toluene) and can degrade TCE (Appl. Environ. Microbiol., 58, 3977 (1992), International Publication No. WO/19738). Also, a mutant not requiring methane as the inducer has been isolated from Methylosinus trichosporium OB3b, a methanotroph capable of degrading TCE (U.S. Patent No. 5316940).

Japanese Patent Application Laid-Open No. 8-294387 also discloses strain JM1 (FERM BP-5352) capable of degrading volatile organic chlorinated compounds and aromatic compounds without requiring an inducer, isolated by nitrosoguanidine mutagenization of strain J1 (FERM BP-5102). While, it has been studied to introduce resting cells expressing TCE-degrading activity into the remediation site after the preculture of the cells in the presence of an inducer (Environ. Sci. Technol., 30, 1982 (1996)).

It has been reported that remediation treatment not requiring the inducer actually makes the remediation treatment easy and efficient compared to the conventional treatment using inducers.

However, the growth control of the degrading microorganisms is very important for both the expression of the degradation activity on demand and the continuation of degradation. When resting cells are used, it is a problem to be solved that TCE cannot be degraded beyond the amount and period of degradation capacity of the introduced resting cells. In addition, in a large scale treatment, there are further problems that degradation activity will decrease since it takes a long time to prepare resting cells; the treating apparatus must be large in scale; treatment process is complicated; and the cost may be unfavorably high. Accordingly, it has been attempted to introduce a plasmid carrying a DNA fragment containing a gene region encoding oxygenase or hydroxylase into a host microorganism to make the host express the TCE degradation activity constitutively or inducibly using a harmless inducer. For example, there are Pseudomonas mendocina KR-1 (Japanese Patent Application Laid-Open No. 2-503866, Pseudomonas putida KWI-9 (Japanese Patent Application Laid-Open No. 6-105691), Pseudomonas putida BH (Summary of 3rd Conference on Pollution of Ground Water/Soil and Its Protective Countermeasure, p.213 (1994)), and a transformant carrying both a toluene degradation enzyme gene derived from Pseudomonas putida F1 and a biphenyl degradation enzyme gene derived from Pseudomonas pseudoalkaligenes

(Japanese Patent Application Laid-Open No. 7-143882).

However, the reported TCE degradation activity of the transformants are low, and the advantages of the transformants has not been fully utilized for efficient degradation of TCE, such as the ease of degradation control, freedom in designing recombinant, and no requirements for inducers.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a novel DNA fragment encoding a toluene monooxygenase of a high efficiency in degrading aromatic compounds and/or organic chlorine compounds, a novel recombinant DNA containing the DNA fragment, and a transformant containing the recombinant DNA. It is another object of the present invention to provide an efficient biodegradation method for volatile organic chlorinated compounds such as trichloroethylene (TCE) and dichloroethylene (DCE) and aromatic compounds such as toluene, benzene, phenol, and cresol using the transformant, specifically an efficient environmental remediation method useful for purifying aqueous media such as wastewater and effluent containing chlorinated aliphatic hydrocarbon compounds or aromatic compounds, remedying soil polluted with chlorinated aliphatic hydrocarbon compounds or aromatic compounds, and purifying air (gas phase) polluted with chlorinated


aliphatic hydrocarbon compounds.

To achieve the above objects, the inventors of the present invention strained to isolate the gene encoding toluene monooxygenase from Burkholderia cepacia KK01

5 (previously Pseudomonas cepacia, deposited in the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology in accordance with the requirements of the Budapest Treaty, Deposit Date: March 11, 1992, Accession No. FERM BP-4235) having a toluene monooxygenase that
10 oxidizes toluene to ortho-cresol and 3-methylcatechol. Successful isolation and characterization of the gene completed the present invention.

According to one aspect of the present invention,
15 there is provided a DNA fragment of about 5.8 Kb containing a toluene monooxygenase gene having a following restriction map, where 1 BamHI restriction site, 2 EcoRI restriction sites, 1 HpaI restriction site, 1 KpnI restriction site, 1 NcoI restriction site,
20 1 NspV restriction site, 1 SacI restriction site, 2 SmaI restriction sites, 3 SphI restriction sites, 2 XhoI restriction sites, no ClaI restriction site, no DraI restriction site, no EcoRV restriction site, no HindIII restriction site, no NdeI restriction site, no
25 NheI restriction site, no PvuII restriction site, no ScaI restriction site, no Sse8387I restriction site, no StuI restriction site, and no XbaI restriction site are

present.



10

According to another embodiment of the present invention, there is provided a DNA fragment having the nucleotide sequence of SEQ ID NO: 1 with deletion, substitution and/or addition of one or more nucleotides, still encoding an active toluene monooxygenase.


15

20

25

Further, according to one aspect of the present invention, there is provided a recombinant DNA comprising a vector enabling maintenance or replication in a host and a DNA fragment of about 5.8 Kb containing a toluene monooxygenase gene having a following restriction map, where 1 BamHI restriction site, 2 EcoRI restriction sites, 1 HpaI restriction site, 1 KpnI restriction site, 1 NcoI restriction site, 1 NspV restriction site, 1 SacI restriction site, 2 SmaI restriction sites, 3 SphI restriction sites, 2 XhoI restriction sites, no ClaI restriction site, no DraI

restriction site, no EcoRV restriction site, no HindIII
restriction site, no NdeI restriction site, no NheI
restriction site, no PvuII restriction site, no ScaI
restriction site, no Sse8387I restriction site, no StuI
5 restriction site, and no XbaI restriction site are
present.



15 Further, according to another embodiment of the
present invention, there is provided another
recombinant DNA comprising a vector enabling
maintenance or replication in a host, and a DNA
fragment ligated thereto having the nucleotide sequence
20 of SEQ ID NO: 1 with deletion, substitution and/or
addition of one or more bases, still encoding an active
toluene monooxygenase.

According to still another aspect of the present
invention, there is provided another recombinant DNA
25 comprising a vector enabling maintenance or replication
in a host, and a DNA fragment containing a region
encoding a toluene monooxygenase, where the region

comprises a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third sequence
5 encoding a polypeptide TomN having an amino acid sequence of SEQ ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an amino acid sequence of SEQ ID NO: 7, and
10 the first to fifth sequences are aligned so that expressed TomL - TomP can form an active monooxygenase protein.

According to still another aspect of the present invention, there is provided another recombinant DNA
15 comprising a vector enabling maintenance or replication in a host, and a DNA fragment containing a region encoding a toluene monooxygenase, where the region comprises a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second
20 sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third sequence encoding a polypeptide TomN having an amino acid sequence of SEQ ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ
25 ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an amino acid sequence of SEQ ID NO: 7, and the first to fifth sequences are aligned so that

expressed TomL - TomP can form an active monooxygenase protein, wherein one or more nucleotides have been deleted, substituted, or added in at least one of the sequences with the proviso that the activity of toluene monooxygenase is not impaired.

According to still another aspect of the present invention, there is provided a DNA fragment containing a region encoding a polypeptide TomK having an amino acid sequence of SEQ ID NO: 2 wherein the function of TomK is to enhance a toluene monooxygenase activity of a protein consisting at least of TomL to TomP, or encoding a variant TomK having an amino acid sequence varied from SEQ ID NO: 2 with the proviso that the function of TomK is not impaired.

According to still another aspect of the present invention, there is provided a recombinant DNA comprising a vector; a promoter; and a DNA fragment containing a region encoding a toluene monooxygenase, where the region comprises a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third sequence encoding a polypeptide TomN having an amino acid sequence of SEQ ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an amino acid sequence of SEQ

ID NO: 7, and the first to fifth sequences are aligned so that expressed TomL - TomP can form an active monooxygenase protein;

5 wherein the promoter is linked to the DNA fragment in a manner allowing expression of the toluene monooxygenase protein encoded by the DNA fragment.

According to still another aspect of the present invention, there is provided a recombinant DNA comprising a vector; a promoter; and a DNA fragment
10 containing a region encoding a toluene monooxygenase, where the region comprises a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third
15 sequence encoding a polypeptide TomN having an amino acid sequence of SEQ ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an amino acid sequence of SEQ
20 ID NO: 7, and the first to fifth sequences are aligned so that expressed TomL - TomP can form an active monooxygenase protein,

wherein one or more nucleotides have been deleted from, substituted in, and/or added to at least one of
25 the sequences of the DNA fragment with the proviso that the protein does not lose toluene monooxygenase activity,

wherein the promoter and the DNA fragment are functionally linked in a manner enabling expression of the toluene monooxygenase protein encoded by the DNA fragment.

5 According to still another aspect of the present invention, there is provided a recombinant DNA comprising a vector; a first promoter and a first DNA fragment functionally linked thereto; and a second promoter and a second DNA fragment functionally linked
10 thereto; wherein the first DNA fragment contains a region encoding a polypeptide TomK having an amino acid sequence of SEQ ID NO: 2 wherein the function of TomK is to enhance a toluene monooxygenase activity of a protein consisting at least of TomL to TomP, or
15 encoding a variant TomK having an amino acid sequence varied from SEQ ID NO: 2 with the proviso that the function of TomK is not impaired; the second DNA fragment contains a region encoding a toluene monooxygenase, where the region comprises a first
20 sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third sequence encoding a polypeptide TomN having an amino acid sequence of SEQ
25 ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an


amino acid sequence of SEQ ID NO: 7, and the first to fifth sequences are aligned so that expressed TomL - TomP can form an active monooxygenase protein, wherein one or more nucleotides have been deleted from,

5 substituted in, and/or added to at least one of the sequences of the second DNA fragment with the proviso that the protein does not lose toluene monooxygenase activity,

wherein the vector is linked to the DNA fragment
10 in a manner enabling expression of the toluene monooxygenase protein encoded by the DNA fragment.

Further, according to still another aspect of the present invention, there is provided a transformant obtainable by introducing a recombinant DNA comprising
15 a vector enabling maintenance or replication in a host and a DNA fragment of about 5.8 Kb containing a toluene monooxygenase gene having a following restriction map, where 1 BamHI restriction site, 2 EcoRI restriction sites, 1 HpaI restriction site, 1 KpnI restriction
20 site, 1 NcoI restriction site, 1 NspV restriction site, 1 SacI restriction site, 2 SmaI restriction sites, 3 SphI restriction sites, 2 XhoI restriction sites, no ClaI restriction site, no DraI restriction site, no EcoRV restriction site, no HindIII restriction site, no
25 NdeI restriction site, no NheI restriction site, no PvuII restriction site, no ScaI restriction site, no Sse8387I restriction site, no StuI restriction site,

and no XbaI restriction site are present.



10 Further, according to still another aspect of the present invention there is provided a transformant obtainable by introducing a recombinant DNA into a host microorganism, where the recombinant DNA comprises a vector enabling maintenance or replication in a host,

15 and a DNA fragment ligated thereto having the nucleotide sequence of SEQ ID NO: 1 with deletion, substitution and/or addition of one or more bases, still encoding an active toluene monooxygenase.

20 Further, according to still another aspect of the present invention, there is provided a transformant obtainable by introducing a recombinant DNA comprising a vector, a promoter and a DNA fragment into a host microorganism where the DNA fragment contains a region encoding a toluene monooxygenase, where the region

25 comprises a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino

5

10

15

25

aspects of the present invention mentioned above.

According to still another aspect of the present invention, there is provided a method for cleaning a medium contaminated with at least either of a
5 chlorinated aliphatic hydrocarbon compound or an aromatic compound, which comprises a step of degrading at least either of a chlorinated aliphatic hydrocarbon compound or an aromatic compound using the transformants according to any one of the aspects of
10 the present invention mentioned above.

According to still another aspect of the present invention, there is provided a method of remedying an environment polluted with at least either of a chlorinated aliphatic hydrocarbon compound or an
15 aromatic compound as a pollutant, comprising a step of degrading the pollutants using the transformant according to any one of the aspects of the present invention mentioned above.

According to still another aspect of the present invention, there is provided a component polypeptide
20 having any one of amino acid sequences of SEQ ID Nos: 2-8, which can constitute a toluene monooxygenase.

According to still another aspect of the present invention, there is provided a toluene monooxygenase
25 comprising at least component polypeptides TomL-TomP of amino acid sequences of SEQ ID NOs: 3-7.

According to still another aspect of the present

invention, there is provided a variant toluene monooxygenase comprising at least component polypeptides TomL-TomP of amino acid sequences of SEQ ID Nos.: 3-7 wherein one or more amino acids have been
5 deleted from, substituted to, and/or added to the polypeptides with the proviso that the toluene monooxygenase does not lose its activity.

BRIEF DESCRIPTION OF THE DRAWINGS

10 Fig. 1 shows a restriction map of a DNA fragment of about 5.8 Kb carrying a toluene monooxygenase gene;

Fig. 2 is comprised of Figs. 2A, 2B, 2C, 2D, 2E, 2F, 2G, 2H, 2I, 2J, 2K, 2L, 2M, 2N, 2O, 2P, 2Q and 2R showing a nucleotide sequence of a toluene
15 monooxygenase gene of FERM BP-4235;

Fig. 3 is an amino acid sequence (TomK) encoded by a region tomK in the nucleotide sequence of Fig. 2;

Fig. 4 is comprised of Figs. 4A, 4B and 4C showing an amino acid sequence (TomL) coded by a region tomL in
20 the nucleotide sequence of Fig. 2;

Fig. 5 is an amino acid sequence (TomM) coded by a region tomM in the nucleotide sequence of Fig. 2;

Fig. 6 is comprised of Figs. 6A, 6B, 6C and 6D showing an amino acid sequence (TomN) coded by a region
25 tomN in the nucleotide sequence of Fig. 2;

Fig. 7 is an amino acid sequence (TomO) coded by a region tomO in the nucleotide sequence of Fig. 2;

Fig. 8 is comprised of Figs. 8A, 8B and 8C showing an amino acid sequence (TomP) coded by a region tomP in the nucleotide sequence of Fig. 2;

Fig. 9 is an amino acid sequence (TomQ) coded by a
5 region tomQ in the nucleotide sequence of Fig. 2;

Fig. 10 is a nucleotide sequence of a first primer employed in Example 6;

Fig. 11 is a nucleotide sequence of a second primer employed in Example 6;

10 Fig. 12 is a nucleotide sequence of a third primer employed in Example 6;

Fig. 13 is a nucleotide sequence of a fourth primer employed in Example 6;

15 Fig. 14 is a nucleotide sequence of a fifth primer employed in Example 6; and

Fig. 15 shows time-course changes in TCE in the gas phase in Example 3.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 The DNA fragment containing a toluene monooxygenase gene according to the present invention is isolated from Burkholderia cepacia strain KK01 (FERM BP-4235, hereinafter referred to as Strain KK01). The microbiological characteristics and culture conditions
25 of Strain KK01 are as follows (see Japanese Patent Application Laid-Open No. 6-22769).

Strain KK01

· Morphological characteristics

(1) Gram staining: Negative

(2) Size and shape: Rod of 1.0-2.0 μm in length and

5 0.5 μm in width

(3) Motility: Motile

B. Growth on various culture media

	Medium	Growth temperature ($^{\circ}\text{C}$)	Growth
10	Blood agar medium	37	+
	Lactose agar medium	37	+
	Chocolate agar medium	37	++
	GMA	37	-
	Scylo	37	-
15	Standard agar medium	4	-
	Standard agar medium	25	\pm
	Standard agar medium	37	+
	Standard agar medium	41	\pm

C. Physiological characteristics

20 (1) Aerobic or anaerobic: Obligate aerobic

(2) Sugar degradation mode: Oxidation

(3) Oxidase production: +

(4) Silver nitrate reduction: +

(5) Hydrogen sulfide production: -

25 (6) Indole production: -

(7) Urease production: -

(8) Gelatin liquefaction: -

(9) Arginine hydrolysis: -

(10) Lysine decarboxylation: +

- (11) Ornithine decarboxylation: -
- (12) Utilization of citric acid: +
- (13) Methyl carbinol acetyl reaction (VP reaction): -
- (14) Detection of tryptophan deaminase: -
- 5 (15) ONPG:
- (16) Assimilation of carbohydrates
- Glucose: +
- Fructose: +
- Maltose: +
- 10 Galactose: +
- Xylose: +
- Mannitol: ±
- Sucrose: -
- Lactose: +
- 15 Esculin: -
- Inositol: -
- Sorbitol: -
- Rhamnose: -
- Melibiose: -
- 20 Amygdalin: -
- L-(+)-arabinose: +

Isolation of the DNA fragment according to the present invention is achieved by partial digestion of the total DNA of strain KK01 with a restriction enzyme

25 Sau3AI. Specifically, total DNA can be prepared by the standard method, in which the above microorganism is grown in a suitable medium, for example, LB medium

(containing 10 g of trypton, 5 g of yeast extract, and 5 g of sodium chloride in 1 litter) and then cells are disrupted, for example, in the presence of sodium dodecyl sulfate (SDS) at 70°C. The total DNA is then
5 partially digested by Sau3AI to obtain a DNA fragment of about 5.8 Kb carrying a toluene monooxygenase gene. The DNA fragment thus obtained is ligated to a plasmid vector completely digested by BamHI, for example, pUC18, and the recombinant vector is introduced into
10 competent cells of, for example, E. coli JM109, prepared by the Hanahan method to obtain transformants. Then, transformants can be selected by a suitable method, for example, by culturing cells on an LB medium plate containing ampicillin.

15 In order to select a transformant containing a recombinant vector carrying a toluene monooxygenase gene from the above transformants, it is preferable to add cresol, phenol, or the like to LB medium for transformant selection in advance. The transformant
20 carrying a toluene monooxygenase gene can be selected as brown colonies, since these substrates are monooxygenated by toluene monooxygenase to produce methylcatechol or catechol which is then autooxidized to develop color. Alternatively, after culturing cells
25 on an ordinary LB medium plate, various substrates may be sprayed onto the plate to select brown colonies in a similar manner.

The isolated DNA fragment of about 5.8 Kb has the following restriction sites:

	Restriction enzyme	Number of restriction sites
5	BamHI	1
	EcoRI	2
	HpaI	1
	KpnI	1
10	NcoI	1
	NspV	1
	SacI	1
	SmaI	2
	SphI	3
15	XhoI	2

The DNA fragment has no ClaI, DraI, EcoRV, HindIII, NdeI, NheI, PvuII, ScaI, Sse8387I, StuI, or XbaI restriction site.

20 The restriction map of the DNA fragment of the present invention is as shown above. Toluene monooxygenase genes derived from Burkholderia cepacia G4 5223 PR1 (U.S. Patent No. 5543317), derived from Burkholderia sp. JS150 (Appl. Environ. Microbiol., 61,

3336 (1995), derived from Pseudomonas pickettii PK01
(J. Bacteriol., 176, 3749 (1994)), and derived from
Pseudomonas mendocina KR1 (J. Bacteriol., 173, 3010
(1991)) were reported. Phenol hydroxylases reported to
5 have a similar structure are derived from Acinetobacter
calcoaceticus NCIIB8250 (Mol. Microbiol., 18, 13
(1995)), Pseudomonas sp. CF600 (J. Bacteriol., 172,
6826 (1990)), Pseudomonas spp. (J. Bacteriol., 177,
1485 (1995)), and Pseudomonas putida P35X (Gene, 151,
10 29 (1994)). The DNA fragment of the present invention
has, however, a restriction map different from any of
those. It is thus clear that the DNA fragment of the
present invention contains a novel toluene
monooxygenase gene.

15 Although the DNA fragment thus obtained can
sufficiently enables the degradation of aromatic
compounds and/or chlorinated aliphatic hydrocarbon
compounds even in pUC18, it can be integrated in an
expression vector or a vector of a wide host range to
20 improve the degradation ability or to be optimized for
the treatment site.

The plasmid according to the present invention can
be constructed from following elements:

- 1) Toluene monooxygenase gene;
- 25 2) Marker gene (drug-resistance, auxotrophic
complement, or the like); and
- 3) Vector containing an autonomous replication

sequence (plasmid, or the like).

As the toluene monooxygenase gene, the DNA
fragment of about 5.8 kb as shown above can be employed
by itself, or a constitution containing elements
5 necessary for a toluene monooxygenase activity can be
also employed, for example, with or without spacer
sequences. Further, each element can be varied with
the proviso that its function is not impaired. These
variations can be attained by changing DNA sequences
10 encoding them.

As the drug-resistance genes, an ampicillin
resistance gene, a kanamycin (G418, neomycin)
resistance gene, a tetracycline resistance gene, a
chloramphenicol resistance gene, a hygromycin
15 resistance gene can be employed. For auxotrophic
complement, a gene sequence to supply the nutrient
required by the host organism is used. Typically, a
gene enabling the synthesis of the required amino acid
is utilized.

20 As the autonomous replication sequences, a
sequence derived from plasmid RSF1010, which can
function as a wide host range replication region in
most of the gram-negative bacteria, can be employed.
It can be also employed vector pBBR122 (Mo Bi Tec)
25 containing a wide host range replication region which
does not belong to any incompatible groups, IncP, IncQ,
or IncW or the like.

For the recombinant plasmid according to the present invention, various promoters and terminators can be employed and various factors can be further introduced to improve and control the ability of degrading aromatic compounds and/or chlorinated aliphatic hydrocarbon compounds. Specifically, promoters such as lac, trc, tac, T3, and T7 can be employed. As a terminator, a rrnB operon terminator or the like can be employed. Also, introduction of a repressor gene such as lacIq and a lac operator enables expression control with an inducer such as isopropyl thiogalactoside (IPTG). Alternatively, the absence of these suppressor and operator as elements, enables constitutive expression of degradation activity. In addition, a temperature-sensitive control system or the like can be employed.

For recombination of a DNA fragment containing the toluene monooxygenase gene into an expression vector containing these regulating elements, natural restriction sites can be utilized as it is, or restriction sites may be newly created by site-directed mutagenesis or a polymerase chain reaction using a primer involving base substitution. In general, recombination into an expression vector often utilizes NcoI restriction sites. It is convenient to design so as to create an NcoI restriction site in the initiation codon ATG or GTG region by site-directed mutagenesis or

primer design. Known methods using an adaptor can be employed. For optimization of expression, the DNA fragment may be properly deleted using exonuclease III or Bal31 nuclease. As described above, molecular
5 biological techniques suitable for the purpose can be employed for recombination into an expression vector.

As a method for introducing the recombinant plasmid carrying a desired gene into a host organism, any methods that can introduce a foreign gene into a
10 host can be employed, and known methods, for example, the calcium chloride method, the electroporation method, and the conjugation transfer method can be employed.

In the present invention, any microorganisms can
15 be used as a host organism so long as it can express the aromatic compounds and/or chlorinated aliphatic hydrocarbon compounds-degrading activity after the introduction of the recombinant plasmid, including the genera Escherichia, Pseudomonas, Burkholderia,
20 Acinetobacter, Moraxella, Alcaligenes, Vibrio, Nocardia, Bacillus, Lactobacillus, Achromobacter, Arthrobacter, Micrococcus, Mycobacterium, Methylosinus, Methylomonas, Welchia, Methylocystis, Nitrosomonas, Saccharomyces, Candida, Torulopsis, and Ralstonia.

25 In addition, the aromatic compounds and/or chlorinated aliphatic hydrocarbon compounds-degrading microorganisms such as strain J1, strain JM1,

Pseudomonas sp. strain TL1, strain KK01, *Pseudomonas alcaligenes* strain KB2, *Alcaligenes* sp. strain TL2, and *Vibrio* sp. strain KB1 can be employed as a host.

These strains have been deposited in the National

5 Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology of Japan. The date of deposit, Accession No., and microbiological characteristics of these strains other than the strain KK01 already described are shown below.

10

Strain J1 (Deposit date: May 25, 1994, Accession No. FERM BP-5102)

A. Morphological characteristics

15

Gram staining: Positive

Size and shape of cells: Polymorphous rod of 1-6 μ m in length and about 0.5-2 μ m in width

Mobility: Negative

Colony: Cream to light pink, sticky

20

B. Growth on various media

BHIA: Good growth

MacConkey: No growth

C. Optimal temperature for growth: 25°C > 30°C > 35°C

25

D. Physiological characteristics

Aerobic or anaerobic: aerobic

TSI (slant/butt): Alkaline/alkaline, H₂S (-)

Oxidase: Negative

Catalase: Positive

Sugar fermentation

Glucose: Negative

5 Sucrose: Negative

Raffinose: Negative

Galactose: Negative

Maltose: Negative

Urease: Positive

10 Esculin: Positive

Nitric acid: Negative

Strain JM1 (Deposit date: January 10, 1995, Accession
No. FERM BP-5352)

15

Gram staining and morphology: Gram-negative rod

Growth on various media

BHIA: Good growth

MacConkey: Possible to grow

20 Colony color: Cream

Optimal temperature for growth: 25°C > 30°C >
35°C

Mobility: Negative (semi-fluid medium)

TSI (slant/butt): Alkaline/alkaline, H₂S (-)

25 Oxidase: Positive (weak)

Catalase: Positive

Sugar fermentation

Glucose: Negative
Sucrose: Negative
Raffinose: Negative
Galactose: Negative
5 Maltose: Negative
Urease: Positive
Esculin hydrolysis (β -glucosidase): Positive
Nitrate reduction: Negative
Indole production: Negative
10 Glucose acidification: Negative
Arginine dehydrase: Negative
Gelatin hydrolysis (protease): Negative
 β -Galactosidase: Negative
Assimilation of compounds
15 Glucose: Negative
L-Arabinose: Negative
D-Mannose: Negative
D-Mannitol: Negative
N-Acetyl-D-glucosamine: Negative
20 Maltose: Negative
Potassium gluconate: Negative
n-Capric acid: Positive
Adipic acid: Negative
dl-Malic acid: Positive
25 Sodium citrate: Positive
Phenyl acetate: Negative
Strain J1 is an aromatic compound-assimilating

bacterium which degrades organic chlorinated compounds with the participation of oxygenase. In spite of its excellent ability of degrading organic chlorinated compounds that it can almost completely degrade about 20 ppm of TCE at a low temperature of 15°C close to natural environment such as soil, it requires aromatic compounds such as phenol, toluene, and cresol as a degradation inducer. Strain JM1 has the same microbiological characteristics as the parental strain J1 except that it can degrade organic chlorinated compounds in the absence of aromatic compounds such as phenol, toluene, and cresol as a degradation inducer.

Strain TL1 (Deposit date: January 10, 1995, Deposit No. FERM P-14726/FERM BP-6923.

- A. Gram staining and morphology: Gram-negative rod
- B. Growth on various media
 - Standard agar: Good growth
 - MacConkey agar: Poor growth
- C. Optimal temperature for growth: 25°C > 35°C
- D. Physiological characteristics
 - Aerobic/anaerobic: Aerobic
 - TSI (slant/butt): Alkaline/alkaline, H₂S (-)
 - Oxidase: Positive
 - Catalase: Positive
 - Oxidation/fermentation test: -/-

- Potassium nitrate reduction: Negative
- Indole production from L-tryptophan: Negative
- Glucose acidification: Negative
- Arginine dehydrase: Negative
- 5 Urease: Negative
- Esculin hydrolysis (β -glucosidase): Negative
- Gelatin hydrolysis (protease): Negative
- β -Galactosidase: Negative
- Cytochrome oxidase: Positive
- 10 E. Assimilation of sugars, organic acids, etc.
- Glucose: Positive
- L-Arabinose: Positive
- D-Mannose: Negative
- D-Mannitol: Positive
- 15 N-Acetyl-D-glucosamine: Negative
- Maltose: Negative
- Potassium gluconate: Positive
- n-Capric acid: Negative
- Adipic acid: Positive
- 20 dl-Malic acid: Negative
- Sodium citrate: Negative
- Phenyl acetate: Negative
- Strain TL2 (Deposit date on November 15, 1994, Deposit
- 25 No. FERM P-14642/FERM BP-6913.
- A. Gram staining and morphology: Gram-negative rod
- B. Growth on various media

Standard agar: Good growth

MacConkey agar: Poor growth

C. Optimal temperature for growth: 25°C >35°C

D. Physiological characteristics

5 Aerobic/anaerobic: Aerobic

TSI (slant/butt): Alkaline/alkaline, H₂S (-)

Oxidase: Positive

Catalase: Positive

Oxidation/fermentation test: -/-

10 Potassium nitrate reduction: Positive

Indole production from L-tryptophan: Negative

Glucose acidification: Negative

Arginine dehydrase: Negative

Urease: Negative

15 Esculin hydrolysis (β -glucosidase): Negative

Gelatin hydrolysis (protease): Negative

β -Galactosidase: Negative

Cytochrome oxidase: Positive

E. Assimilation of sugars, organic acids, etc.

20 Glucose: Negative

L-Arabinose: Negative

D-Mannose: Negative

D-Mannitol: Negative

N-Acetyl-D-glucosamine: Negative

25 Maltose: Negative

Potassium gluconate: Positive

n-Capric acid: Positive

Adipic acid: Positive
dl-Malic acid: Positive
Sodium citrate: Positive
Phenyl acetate: Positive

5

Strain KB1 (Deposit date: November 15, 1994, Deposit
No. FERM P-14643/FERM BP-6914.

- 10 A. Gram staining and morphology: Gram-negative
bacillus
- B. Growth conditions on various media
Standard agar: Good growth
MacConkey agar: Good growth
- 15 C. Optimal temperature for growth: 25°C > 35°C
- D. Physiological characteristics
- Aerobic/anaerobic: Aerobic
- TSI (slant/butt): Alkaline/alkaline, H₂ S(-)
- Catalase: Positive
- Oxidation/fermentation test: -/-
- 20 Potassium nitrate reduction: Positive
- Indole productivity from L-tryptophan: Negative
- Glucose acidification: Negative
- Arginine dehydrase: Positive
- Urease: Positive
- 25 Esculin hydrolysis (β -glucosidase): Negative
- Gelatin hydrolysis (protease): Negative
- β -Galactosidase: Negative

Cytochrome oxidase: Positive

E. Assimilation of sugars, organic acids, etc.

Glucose: Negative

L-Arabinose: Negative

5 D-Mannose: Negative

D-Mannitol: Negative

N-Acetyl-D-glucosamine: Positive

Maltose: Negative

Potassium gluconate: Positive

10 n-Capric acid: Positive

Adipic acid: Positive

dl-Malic acid: Positive

Sodium citrate: Negative

Phenyl acetate: Positive

15

Strain KB2 (Deposit date: November 15, 1994, Accession
No. FERM BP-5354)

A. Gram staining and morphology: Gram-negative rod

20 B. Growth on various media

Standard agar: Good growth

MacConkey agar: Good growth

C. Optimal temperature for growth: 25°C > 35°C

Growth at 42°C: Good

25 D. Physiological characteristics

Aerobic/anaerobic: Aerobic

TSI (slant/butt): Alkaline/alkaline, H₂S (-)

- Catalase: Positive
- Oxidation/fermentation test: -/-
- Potassium nitrate reduction: Positive
- Indole production from L-tryptophan: Negative
- 5 Glucose acidification: Negative
- Arginine dehydrase: Negative
- Urease: Negative
- Esculin hydrolysis (β -glucosidase): Negative
- Gelatin hydrolysis (protease): Negative
- 10 β -Galactosidase: Negative
- Cytochrome oxidase: Positive
- E. Assimilation of sugars, organic acids, etc.
- Glucose: Negative
- L-Arabinose: Negative
- 15 D-Mannose: Negative
- D-Mannitol: Negative
- N-Acetyl-D-glucosamine: Negative
- Maltose: Negative
- Potassium gluconate: Positive
- 20 n-Capric acid: Negative
- Adipic acid: Positive
- dl-Malic acid: Positive
- Sodium citrate: Negative
- Phenyl acetate: Negative
- 25 Further, in order to exploit the microbial
degrading ability more effectively, it is preferable to
select the host microorganism for recombinants from the

microorganisms isolated to the environment to be treated, more preferably a dominant microorganism in the environment, considering environmental adaptation of the recombinant. Generally, in the natural world, microorganisms that have existed in an environment will adapt to the environment most probably, and the probability of the survival of foreign microorganisms introduced into the environment is not high. On the other hand, when a very strong microorganism is introduced from outside, it may disturb the existing ecosystem. Thus, the use of the indigenous microorganisms as a host is a superior method in environmental adaptability, survival, and safety.

A transformant to which a recombinant plasmid has been introduced may be cultured in the conditions suitable for the growth of the host. For example, a carbon and nitrogen source such as yeast extract, trypton, and peptone, and an inorganic salt such as sodium chloride and potassium chloride can be used. An M9 medium (containing 6.2 g of Na_2HPO_4 , 3.0 g of KH_2PO_4 , 0.5 g of NaCl , and 1.0 g of NH_4Cl in 1 liter) supplemented with various minerals and suitable carbon sources such as sodium malate, sodium succinate, sodium lactate, sodium pyruvate, sodium glutamate, sodium citrate, etc. can also be employed. Further, yeast extract, trypton, peptone, etc. can be used in combination. The pH of the growth medium and culture

temperature can be adjusted to those suitable for the host microorganism, although pH of about 5-9 and culture temperature of 15-37°C are generally preferable.

5 A transformant containing a recombinant DNA carrying a toluene monooxygenase gene can be suitably employed for the treatment to degrade chlorinated aliphatic hydrocarbon compounds and aromatic compounds (hereinafter referred to as "pollution compounds")

10 contained in a medium. In other words, the degradation treatment for the pollution compounds according to the present invention can be carried out by bringing the transformant into contact with the pollution compounds in an aqueous medium, soil, or a gas phase. Any method

15 can be used to contact the degrading microorganisms with the pollution compounds so long as the microorganisms can express the degrading activity. Various methods such as a batch method, semi-continuous method, and continuous method can be employed.

20 Microorganisms semi-immobilized or immobilized on an appropriate carrier can be also used. The subject such as polluted water, drainage, waste water, soil, and gas phase can be treated by various methods, as required. These treatment methods are described below.

25 The degradation treatment of the pollution compounds in an aqueous medium according to the present invention can be carried out by contacting the

degrading microorganism with the pollution compounds in the aqueous medium. The representative treating methods are described below. However, the method according to the present invention is not limited thereto, but applicable for any clean-up of the pollution compounds in an aqueous medium.

The simplest method is, for example, to introduce the degrading microorganism directly into an aqueous medium contaminated with the pollution compounds. In this case, it is preferable to optimize the pH, salt concentrations, temperature, and pollutant concentrations of the aqueous medium according to the degrading microorganism.

As another application mode, the degrading microorganism is grown in a culture vessel, and an aqueous medium containing the pollution compounds is introduced into the vessel at a predetermined flow rate to degrade these compounds. The aqueous medium can be introduced and discharged continuously, intermittently or batch-wise according to the treatment capacity. It is preferable to optimize the system by a system control in accordance to the concentrations of the pollution compounds.

Alternatively, the degrading microorganism may be first attached to a carrier such as soil particles and the filled in a reactor vessel, to which an aqueous medium containing the pollution compounds is introduced

for degradation treatment. In this case, any carrier can be employed not restricted to soil particles, but carriers having a high capacity to retain microorganisms and not preventing aeration are preferable. To provide the microorganism with habitats, it can be used various bioreactor carriers, for example, those conventionally employed in the pharmaceutical industry, food industry, and wastewater treatment systems. More specifically, there can be used inorganic particulate carries such as porous glass, ceramics, metal oxides, activated carbon, kaolinite, bentonite, zeolite, silica gel, alumina, and anthracite; gel carries such as starch, agar, chitin, chitosan, polyvinyl alcohol, alginic acid, polyacrylamide, carrageenan, and agarose; ion-exchange cellulose, ion-exchange resins, cellulose derivatives, glutaraldehyde, polyacrylic acid, polyurethane, polyester, or the like. As natural materials, cellulose materials such as cotton, hemp, and papers, and lignin materials such as saw dust and barks can be employed.

The degradation treatment of the pollution compounds in soil according to the present invention can be carried out by bringing the degrading microorganism in contact with the pollution compounds in the soil. The representative treating methods are described below. However, the method according to the

present invention is not limited thereto but applicable to any clean-up of the pollution compounds in soil.

The simplest method is, for example, to introducing degrading microorganisms directly into the soil polluted with the pollution compounds.

5 Introduction of the microorganism may be carried out by spraying it on the surface of the soil and, when the treatment extends to deep underground, by introducing it through the well arranged in the underground,

10 wherein the application of pressure of air, water, etc. allows the microorganism to spread over the wide area of the soil and makes the process more effective. In this case, it is necessary to adjust various conditions of the soil so that they are suitable for the

15 microorganism used for the process.

Another use is such that first the microorganism is attached to a carrier, next the carriers are charged into the reaction vessel, and then the reaction vessel is introduced into, primarily, the aquifer of the

20 contaminated soil, to undergo degradation treatment.

The form of the reaction vessel is desirably like a fence or a film which can cover the wide area of the soil. Any carrier can be used, but it is preferable to use those having an excellent retention of

25 microorganisms and not inhibiting aeration. As a material of the carrier, which can provide suitable habitats for microorganisms, for example, it can be

used various bioreactor carriers, for example, those conventionally employed in the pharmaceutical industry, food industry, and wastewater treatment systems.

According to the present invention, the
5 degradation treatment of the pollution compounds in gas phase can be achieved by contacting the microorganism with the contaminants in the gas phase. The representative modes are shown below, but are not intended to limit the present invention. The present
10 invention is applicable to purification treatment of any gas phase contaminated with the pollution compounds.

One mode is, for example, such that the degradation microorganism is cultured in a culture
15 vessel, and then the gas containing the pollution compounds is introduced into the vessel at a given flow rate to undergo degradation treatment. The method of introducing the gas is not limited specifically, but it is desirably such that introduction of the gas causes
20 agitation of the culture medium and promote its aeration. Introduction and discharge of the gas may be carried out continuously, or it may be carried out intermittently according to the degradation capacity. A batch method is also applicable. Preferably such
25 control is systematized in accordance with the concentrations of the pollution compounds to give optimum results.

Another mode is such that the microorganism is attached to a carrier like soil particles, next the carriers are put into a reaction vessel, and then the gas containing the pollution compounds is introduced into the vessel to undergo degradation treatment. Besides particles of soil, any carrier can be used, however, it is desirable to use those having an excellent retention of microorganisms and not inhibiting aeration. As a material of the carrier, which can provide suitable habitats for microorganisms, for example, it can be used various bioreactor carriers, for example, those conventionally employed in the pharmaceutical industry, food industry, and wastewater treatment systems.

As materials which can retain the degrading microorganism and supply it with nutrient, many examples can be found in the compost used in the agriculture, forestry and fisheries. Specifically, dry materials from plants, such as straw of grains, sawdust, rice bran, bean curd lees, bagasse and so on, and seafood wastes, such as shells of crabs and lobster and so on are applicable.

In purification of contaminated gas, the degrading microorganism may be introduced after the carrier material is packed. To make the degradation reaction efficient, it is preferable that the above-mentioned nutrient, water content, oxygen concentration, etc. are

kept in desirable conditions. The ratio of the carrier to water in a reaction vessel may be determined considering the growth of the microorganism and aeration. The shape of the vessel may be selected
5 considering the amount and concentration of the gas undergoing treatment, but preferably it is designed to enhance the contact of the gas with the microorganism held on the carrier. For example, column, tube, tank and box type are applicable. The vessel of these forms
10 may be joined together with an exhaust duct and a filter to form one unit, or plural vessels may be connected according to the capacity.

Contaminated gas is sometimes adsorbed by the carrier material in the beginning of the reaction and
15 there is very few case where the effect of utilizing microorganism may not be exhibit. After a certain period of time, however, it is thought that the contaminants adhered to the carrier material is degraded, and further contaminants can be adsorbed by
20 the surface of the material to restore adsorption of the material. Thus, a constant decomposition rate is expected without saturation of the pollutant-eliminating ability.

The method according to the present invention is
25 applicable for the treatment of waste liquid, soil and air in a closed system or open system. Moreover, microorganisms may be immobilized on a carrier, or

various methods promoting their proliferation may be employed in combination.

The present invention is explained more specifically by means of the following examples.

5 <Example 1>

-Cloning of toluene monooxygenase gene of strain KK01-

Cells of strain KK01 (FERM BP-4235) which can
assimilate toluene were cultured in 100 ml of LB medium
(containing 10 g of trypton, 5 g of yeast extract, and
10 5 g of sodium chloride in 1 liter) overnight, harvested
and washed with 100 mM phosphate buffer (pH 8.0). To
the cells thus obtained, 10 ml of STE (10 mM tris (pH
8.0)/1 mM EDTA/100 mM sodium chloride) and 1 ml of 10%
sodium dodecyl sulfate (final concentration of about
15 1%) were added. After the cells were incubated at 70°C
for 30 minutes for lysis, phenol treatment and ethanol
sedimentation were carried out. DNA thus obtained was
dissolved in a 10 mM tris (pH 8.0)/1 mM EDTA buffer
(TE).

20 The DNA thus obtained was dissolved at various
concentrations and treated with a restriction enzyme
Sau3AI (Takara Shuzo Co., Ltd.) at 37°C for 15 minutes
for partial digestion. Aliquots of the partial
digestion products were applied to gel electrophoresis
25 on 0.8% agarose gel to identify the samples almost
digested to about 5-10 kb. These samples were applied
to spin column HR-400 (Amersham-Pharmacia) to purify

DNA fragments.

The DNA fragments were ligated to plasmid pUC18 (Takara Shuzo Co., Ltd.) completely digested with a restriction enzyme BamHI (Takara Shuzo Co., Ltd.) and dephosphorylated with BAP (Takara Shuzo Co., Ltd.), using DNA Ligation Kit Ver. 2 (Takara Shuzo Co., Ltd.). Recombinant plasmids thus prepared were then introduced into the host E. coli HB101 (Takara Shuzo Co., Ltd.), and the cells were cultured on LB agar plates containing 100 µg/ml of ampicillin as a selection agent and 200 ppm phenol as an indicator for toluene monooxygenase activity. About 15,000 colonies of transformants grew on the plates.

Eight brown colonies were found in these colonies and picked up. Recombinant plasmid DNA carrying toluene monooxygenase gene was extracted from the cells of each brown colony and the restriction map thereof was determined. It was found that all recombinant plasmids derived from the 8 colonies had a common insertion fragment of 5.8 kb. A plasmid containing only the common fragment of 5.8 kb was designated as pKK01 and a restriction map of the inserted DNA fragment was made (See Fig. 1). A recombinant E.coli HB101 carrying a plasmid containing a 8.5 kb insertion fragment containing this common 5.8 kb fragment was deposited in the National Institute of Bioscience and Human Technology, Agency of Industrial Science and

Technology in accordance with the Budapest Treaty under the accession No. FERM BP-6916. Its microbiological characteristics were identical to those of E. coli HB101 except that it can degrade aromatic compounds and chlorinated aliphatic hydrocarbon compounds.

In order to confirm that the inserted DNA fragment of pKK01 was derived from strain KK01, southern hybridization was performed. DNA was extracted from strain KK01 and completely digested with EcoRI (Takara Shuzo Co., Ltd.) or XhoI (Takara Shuzo Co., Ltd.), and then subjected to southern hybridization. The inserted DNA fragment of pKK01 was digested with BamHI-KpnI (Takara Shuzo Co., Ltd.) to obtain a DNA fragment of about 1.6 kb, and this was used as a probe. As a result, a strong signal was observed around 4.3 kb with the EcoRI-digested DNA, and around 4.2 kb with the XhoI digested DNA, in a good agreement with the lengths of the fragments predicted from the restriction map. Consequently, it was confirmed that the toluene monooxygenase gene contained in pKK01 was derived from the strain KK01.

<Example 2>

-Monooxygenation by E. coli HB101(pKK01)-

The cells of E.coli HB101(pKK01) were inoculated in 100 ml of LB medium, cultured at 37°C overnight, harvested, washed, and then resuspended in 100 ml of M9

medium (6.2 g of Na_2HPO_4 , 3.0 g of KH_2PO_4 , 0.5 g of NaCl , and 1.0 g of NH_4Cl per liter) supplemented with a mineral stock solution of the following composition (3 ml/liter of M9 medium)(referred to as M9 + mineral solution).

Composition of mineral stock solution

	Nitrilotriacetic acid	:	1.5 g
	MgSO_4	:	3.0 g
	CaCl_2	:	0.1 g
10	Na_2MoO_4	:	0.1 g
	FeSO_4	:	0.1 g
	MnSO_4	:	0.5 g
	NaCl	:	1.0 g
	ZnSO_4	:	0.1 g
15	CuSO_4	:	0.1 g
	$\text{AlK}(\text{SO}_4)_2$:	0.1 g
	H_3BO_3	:	0.1 g
	NiCl_2	:	0.1 g

Distilled water (to 1,000 ml)

20 Then, 27.5 ml vials were prepared, and 10 ml aliquot of the above suspension was placed in each vial, which was then tightly sealed with a teflon-coated butyl rubber stopper and aluminum seal. Gaseous toluene or benzene was introduced into each vial with a
25 syringe to a concentration of 100 ppm (a concentration supposing all toluene or benzene completely dissolved

in the aqueous phase in the vial). After incubation at 30°C for 3 hours, 1 ml aliquot was taken from each vial, and cells were removed by centrifugation and substances of 10,000 or higher in molecular weight were removed by ultrafiltration. Production of ortho-cresol and 3-methylcatechol from toluene and phenol and catechol from benzene was confirmed by HPLC, to show that toluene and benzene are monooxygenated by toluene monooxygenase encoded by the cloned DNA fragment.

<Example 3>

-Degradation of aromatic compounds and chlorinated aliphatic hydrocarbon compounds by E.coli HB101(pKK01)-

The cells of E.coli HB101(pKK01) cultured as described in Example 2 were suspended in M9 + mineral solution. Ten ml aliquots of the suspension were placed in 27.5 ml vials. Each vial was tightly sealed with a teflon-lined butyl rubber stopper and an aluminum seal. Gaseous trichloroethylene (TCE), cis-1,2-dichloroethylene (cis-1,2-DCE), trans-1,2-dichloroethylene (trans-1,2-DCE), 1,1-dichloroethylene (1,1-DCE), toluene, and benzene were injected into respective vials to a concentration of 5 ppm (a concentration supposing the introduced substance completely dissolved in the aqueous phase in the vial). The vials were shaken and incubated at 30°C. The concentrations of the respective compounds in the gas

phase were measured by gas chromatography after 6 hours. The results are shown in Table 1. E.coli HB101 harboring pUC18 (E.coli HB101(pUC18)) was employed as a control and degradation was evaluated in the same manner.

Another experiment was carried out on TCE degradation in the same manner except that the initial TCE concentration was 10 ppm and when the TCE concentration in the gas phase reached about 0, the process was repeated for total three times. The results are shown in Table 2.

Similarly, phenol, ortho-cresol, meta-cresol and para-cresol were introduced into respective 27.5 ml vials each containing 10 ml of the cell suspension at a concentration of 50 ppm. Each vial was tightly sealed with a butyl rubber stopper and aluminum seal. The vials were shaken and incubated at 30°C. The quantities of the respective compounds in the liquid phase were determined by the amino antipyrine method with a spectrophotometer to obtain their concentrations after 6 hours. The results are shown in Table 2. E.coli HB101(pUC18) was employed as a control and degradation was evaluated in the same manner.

[Table 1]

	E.coli HB101(pKK01)	HB101(pUC18)
TCE	0	5.2
cis-1,2-DCE	0	4.9
trans-1,2-DCE	0	5.1
1,1-DCE	0	5.3
Toluene	0	5.5
Benzene	0	4.9

(Unit: ppm)

[Table 2]

	E.coli HB101(pKK01)	E.coli HB101(pUC18)
Phenol	0	55
Ortho-cresol	0	49
Meta-cresol	0	47
Para-cresol	0	52

(Unit: ppm)

The above results show that E.coli HB101(pKK01) had an excellent ability to degrade aromatic compounds and chlorinated aliphatic hydrocarbon compounds.

<Example 4>

-Definition of toluene monooxygenase region-

The toluene monooxygenase region was defined further by subcloning or stepwise deletion of plasmid pKK01 obtained in Example 1, using restriction sites

thereof. Toluene monooxygenase activity was evaluated by the method in Example 3, and 5 ppm toluene was employed as a substrate.

First, a subclone pKK01 Δ BamHI in which a 0.7-kb
5 fragment was deleted was prepared from pKK01 using the
unique BamHI site at 0.7 kb. More specifically, pKK01
was completely digested by restriction enzymes BamHI
and HindIII (Takara Shuzo Co., Ltd.) to obtain 2
fragments of 3.4 kb and 5.1 kb. The fragments were
10 separated by agarose gel electrophoresis, and the 5.1
kb fragment was cut out and recovered from the gel and
purified with a spin column HR-400 (Amersham-
Pharmacia). The fragment was ligated to pUC18
previously completely digested by BamHI and HindIII
15 enzymes, and E.coli HB101 was transformed with the
recombinant plasmids according to the conventional
method. E.coli HB101 cells were then applied on an LB
plate containing 100 μ g/ml of ampicillin to select
transformants. From the cells grown overnight in LB
20 medium, plasmid DNA was extracted by an alkaline method
to confirm the presence of pKK01 Δ BamHI, and a
transformant carrying pKK01 Δ BamHI was isolated. E.coli
HB101 (pKK01 Δ BamHI) cells were evaluated for toluene
monooxygenase activity. No degradation of toluene was
25 observed, indicating that the 0.7-kb fragment is
essential for toluene monooxygenase activity.

Then, a subclone pKK01 Δ EcoRI was prepared by

deleting a 0.3 kb fragment from pKK01 using the 0.3 kb EcoRI restriction site of pKK01. More specifically, pKK01 was partially digested by restriction enzyme EcoRI, and then self-ligated to transform E.coli HB101.

5 The E.coli HB101 transformants were then selected on an LB plate containing 100 µg/ml of ampicillin. After the transformants were cultured in LB medium overnight, the plasmid DNA was extracted from the cells by the alkaline method to confirm the presence of pKK01ΔEcoRI and a transformant carrying pKK01ΔEcoRI was isolated. 10 E. coli HB101(pKK01ΔEcoRI) was evaluated for toluene monooxygenase activity. Degradation of toluene was observed, but the activity was lower than that of E.coli HB101(pKK01), indicating that the 0.3 kb 15 fragment was not essential for toluene monooxygenase activity but necessary for full expression of the activity.

Further, the stepwise deletion method was employed to restrict the toluene monooxygenase region from the 20 opposite direction. More specifically, stepwise deletion was introduced from the XbaI restriction site using XbaI (Takara Shuzo Co., Ltd.) restriction site and Sse8387I (Takara Shuzo Co., Ltd.) restriction site of pUC18. The step-wise deletion was carried out using 25 Deletion Kit for Kilo-Sequence (Takara Shuzo Co., Ltd.) according to the experimental method described in the attached protocol. The results of the activity

evaluation of various deletion clones thus obtained
show that the region up to 4.9 kb is essential for
expression of the activity and a region from 4.9 kb to
5.8 kb is not especially required for degradation
5 activity.

<Example 5>

-Sequencing of Toluene Monooxygenase Gene-

The nucleotide sequence of pKK01 was determined as
10 follows. pKK01 was digested by various restriction
enzymes and subcloned into pUC18 plasmid. Deletion
clones were prepared from pKK01 or subclones of partial
pKK01 using Deletion Kit for Kilo-Sequence (Takara
Shuzo Co., Ltd.) to determine the nucleotide sequence
15 of the 5.8-kb fragment encoding toluene monooxygenase
by the dideoxy method. The dideoxy method was carried
out using ABI PRISM Cycle Sequencing Kit (Perkin Elmer
Corporation) according to the attached protocol for
reaction conditions, etc. DNA recombination and Kilo-
20 Sequence method were also performed according to the
conventional methods or the manufacturer's protocols
attached. The results of sequencing show that the DNA
encoding toluene monooxygenase is contained in 5,828
bases comprised of 7 coding regions as shown by SEQ ID
25 NO: 1; a region tomK encoding the amino acid sequence
TomK of SEQ ID NO: 2 ; a region TomL encoding the amino
acid sequence tomL of SEQ ID NO: 3; a region tomM

encoding an amino acid sequence TomM of SEQ ID NO: 4; a region tomN encoding an amino acid sequence TomN of SEQ ID NO: 5; a region tomO encoding an amino acid sequence (TomO) of SEQ ID NO: 6; a region tomP encoding an amino acid sequence TomP of SEQ ID NO: 7; and a region tomQ encoding an amino acid sequence TomQ of SEQ ID NO: 8.

Here, considering the results of Example 4 together, the polypeptide (TomK)(SEQ ID No: 2) encoded by tomK is not essential for expression of the activity but the presence of TomK clearly enhances the toluene monooxygenase activity. It is therefore desirable for sufficient expression of the activity that TomK is present as a component of toluene monooxygenase. The polypeptide (TomQ)(SEQ ID NO: 8) encoded by tomQ is not essential for expression of the activity. In addition, the toluene monooxygenase activity is not affected by the presence of TomQ. Thus, it is not essential to contain TomQ as a component of toluene monooxygenase.

In other words, any DNA fragment containing segments encoding the amino acid sequences of SEQ ID NOs: 3-7 as the components of toluene monooxygenase where these segments are aligned so that expressed TomL to TomP having the amino acid sequences of SEQ ID NOs: 3-7 can form a protein with a toluene monooxygenase activity is included in the preferred DNA fragment of the present invention. DNA fragments with variation in

at least one segment of the DNA fragment with the proviso that the activity of toluene monooxygenase is not impaired are included in the preferred DNA fragments of the present invention.

5 DNA fragments further containing a region encoding the amino acid sequence TomK of SEQ ID NO: 2 or a variant in which the amino acid sequence of SEQ ID NO: 2 is changed with the proviso that it does not impair the property to enhance a toluene monooxygenase
10 activity are also included in the preferred embodiment of the present invention.

 It should be noted that, in tomK, a sequence corresponding to SD sequence is not found before the 1st ATG (216-218) but present before the 2nd ATG (234-
15 236). Thus, in the following Sequence Listing, the polypeptide encoded by the nucleotide sequence beginning the base number 234 is designated as TomK.

 In addition, in tomL, a sequence corresponding to SD sequence is not found before the 1st ATG (bases
20 number 391-393) but present before GTG(463-465). Thus, in the following Sequence Listing, the polypeptide encoded by the nucleotide sequence beginning the base of number 463 is designated as SEQ ID: NO.3 (TomL).

<Example 6>

-Recombination of Toluene Monooxygenase Gene into
Expression Vectors-

As expression vectors, pTrc99A (Amarsham-
5 Pharmacia), pSE280 (Invitrogen), and pSE380
(Invitrogen) were employed. They contain an
ampicillin-resistant gene as a marker, and pTrc99A has
a sequence derived from pBR322, and pSE280 and pSE380
have those derived from ColE1 as ori. All these 3
10 vectors contain a trc promoter and a rrnB terminator,
and a ribosome-binding site is located before the NcoI
restriction site. lacIq is contained in pTrc99A and
pSE380 but not in pSE280.

To incorporate the toluene monooxygenase gene into
15 these vectors, NcoI restriction sites were introduced
in tomK and tomL. The following 5 primers (Takara
Shuzo Co., Ltd.) were prepared to introduce the NcoI
restriction site by PCR:

20	SEQ ID	tom-K1 5'-	
	NO: 9	AGTCCGCCATGGAGGCGACACCGATCATGAATCAGC-3'	36 mer
	SEQ ID	tom-K2 5'-	
	NO: 10	CACCGACCATGGATCAGCACCCACCGATCTTTC-3'	34 mer
	SEQ ID	tom-L1 5'-	
25	NO: 11	TGCCGCCTTCCATGGGTTCTGCCGGAACAGCAG-3'	34 mer
	SEQ ID	tom-L2 5'-	
	NO: 12	AGCAAGCCATGGCCATCGAGCTGAAGACAGTCGACATCA- 3'	39 mer
	SEQ ID	tail 5'-	
	NO: 13	CCGACCATCACCTGCTCGGCCAGATGGAAGTCGAG-3'	35 mer

30

The tom-K1 was designed to introduce the NcoI restriction site at the 1st ATG region (bases 216-218 in the Sequence Listing) of tomK. Similarly, tom-K2 was designed to introduce the NcoI site at the 2nd ATG region (bases 234-236 in the SEQ ID NO: 1) of tomK;
5 tomL-1 was designed to introduce the NcoI site at the 1st ATG region (bases 391-393 in SEQ ID NO: 1) of tomL; and tom-L2 was designed to introduce the NcoI site at the 1st GTG region (bases 463-465 in SEQ ID NO: 1) of
10 tomL. Using primer combinations of the primer (5) with the respective primers (1)-(4) and the 8.5 kb fragment-containing plasmid DNA of FERM BP-6916 as the template, PCR was performed. PCR was carried out using Takara LA PCR Kit Ver. 2 (Takara Shuzo Co., Ltd.) with a reaction
15 volume of 50 µl, repeating 30 times a cycle of reaction at 94°C for 1 minute and 98°C for 20 seconds followed by 72°C for 5 minutes (shuttle PCR), then followed by reaction at 72°C for 10 minutes. The reaction conditions were according to the manufacturer's
20 protocol.

As a result, the combinations of the primers (1) and (5), (2) and (5), (3) and (5), and (4) and (5) gave the PCR products of about 5.6 kb, about 5.6 kb, about 5.4 kb, and about 5.4 kb, respectively. The respective
25 DNA fragments were digested with the restriction enzyme NcoI (Takara Shuzo Co., Ltd.) to give the respective fragments of about 5.0 kb, about 5.0 kb, about 4.9 kb,

and about 4.8 kb together with a fragment of about 0.6 kb. It shows that PCR products were completely digested by the restriction enzyme NcoI. These NcoI-digested products were purified using a spin column HR-4000 (Amarsham-Pharmacia) and used for the following ligation reaction.

The above expression vectors were completely digested with the restriction enzyme NcoI, dephosphorylated, subjected to phenol treatment, and purified with a spin column HR-400 (Amarsham-Pharmacia). The vectors were then ligated to the NcoI-digested PCR products to transform E.coli HB101 (Takara Shuzo Co., Ltd.) according to the conventional method. The transformed E.coli HB101 cells were then grown on LB plate containing 100 µg/ml of ampicillin for transformant selection. After the transformants were cultured in LB medium at 37°C overnight, plasmid DNA was extracted by the alkaline method to examine the recombinant plasmids. Transformants in which the respective PCR fragments were accurately inserted into the NcoI restriction site of the respective expression vectors were obtained.

A list of the obtained recombinant plasmids are shown in Table 3.

[Table 3]

	tom-K1	tom-K2	tom-L1	tom-L2
pTrc99A	pK19	pK29	pL19	pL29
pSE280	pK12	pK22	pL12	pL22
pSE380	pK13	pK23	pL13	pL23

<Example 7>

-Ability of E.coli HB101 Recombinant Strains to Degrade
Aromatic Compounds and Chlorinated Aliphatic

Hydrocarbon Compounds (without Induction with IPTG)-

The cells of the E.coli strains, each harboring
one of the 12 recombinant plasmids obtained as
described in Example 6, were inoculated in 100 ml of LB
medium, cultured at 37°C overnight, harvested, washed,
and suspended in an M9 + mineral solution. Ten ml
aliquots of the suspension were placed in 27.5 ml
vials, and each vial was tightly sealed with a Teflon-
coated butyl rubber stopper and aluminium seal. Then,
gaseous trichloroethylene (TCE), cis-1,2-
dichloroethylene (cis-1,2-DCE), trans-1,2-
dichloroethylene (trans-1,2-DCE), 1,1-dichloroethylene
(1,1-DCE), toluene, and benzene were added to
respective vials with a syringe to a concentration of
20 ppm (supposing all of the introduced substance

dissolved in the aqueous phase in the vial). The vials were shaken and incubated at 30°C. The concentrations of the respective compounds in the gas phase after 6 hour incubation were measured by gas chromatography.

- 5 The results are shown in Table 4. E.coli HB101(pSE280) was employed as a control and degradation was evaluated in the same manner.

[Table 4]

	pK19	pK29	pL19	pL29	pK12	pK22	pL12	pL22
TCE	4.5	5.2	7.8	7.5	0	0	0.4	0.2
cis-1,2-DCE	2.5	2.4	3.8	4.5	0	0	2.1	3.2
trans-1,2-DCE	3.1	4.2	5.2	5.8	0	0	1.5	1.4
1,1-DCE	7.2	6.6	8.9	9.1	0	0	1.2	0.9
Toluene	1.3	1.1	2.5	3.2	0	0	0	0
Benzene	4.8	5.1	7.3	6.8	0	0	0.9	0.5
	pK13	pK23	pL13	pL23	pSE280			
TCE	3.8	4.3	5.5	5.3	20.1			
cis-1,2-DCE	0.9	0.7	1.5	1.8	18.9			
trans-1,2-DCE	1.2	1.1	2.1	2.1	19.8			
1,1-DCE	2.5	2.4	5.1	4.9	20.7			
Toluene	1.2	0.9	1.8	1.7	21.0			
Benzene	3.5	3.3	4.8	4.4	20.2			

(Unit: ppm)

Similarly, phenol, ortho-cresol, meta-cresol and para-cresol were introduced into respective 27.5 ml vials each containing 10 ml of the cell suspension at a concentration of 50 ppm. Each vial was tightly sealed with a butyl rubber stopper and aluminum seal. The vials were shaken and incubated at 30°C. The quantities of the respective compounds in the liquid

phase were determined by the amino antipyrine method with a spectrophotometer to determine their concentrations after 6 hours. The results are shown in Table 5. E.coli HB101(pSE280) was employed as a control and degradation was evaluated in the same manner.

[Table 5]

	pK19	pK29	pL19	pL29	pK12	pK22	pL12	pL22
Phenol	0	0	0	0	0	0	0	0
Ortho-cresol	0	0	0	0	0	0	0	0
Meta-cresol	0	0	0	0	0	0	0	0
Para-cresol	0	0	0	0	0	0	0	0
	pK13	pK23	pL13	pL23	pSE280			
Phenol	0	0	0	0	50.6			
Ortho-cresol	0	0	0	0	52.5			
Meta-cresol	0	0	0	0	53.1			
Para-cresol	0	0	0	0	50.5			

(Unit: ppm)

The above results confirm that E.coli HB101 transformants harboring the expression vectors have an excellent ability to degrade the aromatic compounds and chlorinated aliphatic hydrocarbon compounds. It is shown that transformants harboring pTrc99A or pSE380-derived expression vectors express a lower degrading activity in a system not containing IPTG than those harboring pSE280-derived plasmids, since pSE280 lacks lacIq.

<Example 8>

-Ability of E.coli HB101 Transformants harboring Expression Vectors to Degrade Aromatic Compounds and Chlorinated Aliphatic Hydrocarbon Compounds (with Induction with IPTG)-

Each E.coli HB101 transformant strain harboring one of the 12 recombinant plasmids obtained as described in Example 6, was inoculated in 100 ml of LB medium, cultured at 37°C to reach OD₆₀₀ of about 0.8, and then IPTG was added to 1 mM concentration followed by further incubation at 37°C for 5 hours. Then the cells were harvested, washed and suspended in an M9 + mineral solution. Ten ml aliquots of the suspension were placed in 27.5 ml vials, and each vial was tightly sealed with a Teflon-coated butyl rubber stopper and aluminium seal. Then, gaseous trichloroethylene (TCE), cis-1,2-dichloroethylene (cis-1,2-DCE), trans-1,2-

dichloroethylene (trans-1,2-DCE), 1,1-dichloroethylene (1,1-DCE), toluene, and benzene were added to respective vials with a syringe to a concentration of 20 ppm (supposing all of the introduced substance dissolved in the aqueous phase in the vial). The vials were shaken and incubated at 30°C. The concentrations of the respective compounds in the gas phase after 6 hour incubation were measured by gas chromatography. The results are shown in Table 6. E.coli HB101(pSE280) was employed as a control and degradation was evaluated in the same manner.

[Table 6]

		pK19	pK29	pL19	pL29	pK12	pK22	pL12	pL22
	TCE	0	0	0	0	0	0	0.7	0.5
	cis-1,2-DCE	0	0	0	0	0	0	1.9	2.1
5	trans-1,2-DCE	0	0	0	0	0	0	0.9	1.9
	1,1-DCE	0	0	0.7	0.5	0	0	0.8	0.7
	Toluene	0	0	0	0	0	0	0	0
	Benzene	0	0	1.2	2.1	0	0	1.3	0.9
10		pK13	pK23	pL13	pL23	pSE280			
	TCE	0	0	0	0	21.2			
	cis-1,2-DCE	0	0	0	0	19.9			
	trans-1,2-DCE	0	0	0	0	20.7			
15	1,1-DCE	0	0	0	0	19.8			
	Toluene	0	0	0	0	20.5			
	Benzene	0	0	0.3	0.1	21.0			

(Unit: ppm)

Similarly, phenol, ortho-cresol, meta-cresol and para-cresol were introduced into respective 27.5 ml vials each containing 10 ml of the cell suspension, at a concentration of 50 ppm. Each vial was tightly sealed with a butyl rubber stopper and aluminum seal. The vials were shaken and incubated at 30°C. The quantities of the respective compounds in the liquid phase were determined by the amino antipyrine method with a spectrophotometer to determine their concentrations after 6 hours. The results are shown in Table 7. E.coli HB101(pSE280) was employed as a control and degradation was evaluated in the same manner.

[Table 7]

	pK19	pK29	pL19	pL29	pK12	pK22	pL12	pL22
Phenol	0	0	0	0	0	0	0	0
Ortho-cresol	0	0	0	0	0	0	0	0
Meta-cresol	0	0	0	0	0	0	0	0
Para-cresol	0	0	0	0	0	0	0	0
	pK13	pK23	pL13	pL23	pSE280			
Phenol	0	0	0	0	50.0			
Ortho-cresol	0	0	0	0	51.1			
Meta-cresol	0	0	0	0	52.3			
Para-cresol	0	0	0	0	47.9			

(Unit: ppm)

15 The above results confirm that E.coli HB101
transformants harboring toluene monooxygenase-
expression vectors has an excellent ability to degrade
aromatic compounds and chlorinated aliphatic
hydrocarbon compounds. It is shown that transformants
20 harboring pTrc99A- or pSE380-based expression vectors
show more excellent degrading activity by IPTG

induction.

<Example 9>

-TCE Degradation by E.coli HB101(pK22) and HB101(pK23)

5 recombinant Strains in Soil (Without IPTG Induction)-

E.coli HB101(pK22) and HB101(pK23) recombinant strains as described in Example 6 were respectively inoculated in 10 ml of LB medium and cultured at 37°C overnight. Fifty grams of Sawara sieved sand

10 (unsterilized) was placed in 68 ml vials each. Five ml of LB medium inoculated with the above seed culture to 100:1, was then added to the sand in each vial. Each vial was cotton-plugged, and incubated at 37°C for 8 hours without shaking. After that, each vial was

15 tightly sealed with a Teflon-coated butyl rubber stopper and aluminum seal. Gaseous TCE was introduced into the vials with a syringe to 20 ppm (supposing all TCE dissolved into the aqueous phase in the vial). The vials were incubated at 30°C. Quantitative analysis of

20 TCE in the gas phase were carried out by gas chromatography after 6 hours to determine TCE concentrations. The results are shown in Table 8. E.coli HB101(pSE280) was employed as a control and evaluated in the same manner.

25

[Table 8]

	pK22	pK23	pSE280
TCE	0	2.4	20.8

5 (Unit: ppm)

The above results confirm that E.coli HB101 transformants harboring pK22 and pK23 also show an excellent TCE-degrading ability in soil. It is shown
10 that transformant harboring pK23 (pSE380-based) expresses a lower degrading activity in a system not containing IPTG than that harboring pSE280-derived plasmid pK23, since the former contains lacIq.

15 <Example 10>

-TCE Degradation by E.coli HB101(pK22) or HB101(pK23) in Soil (With IPTG Induction)-

The cells of E.coli HB101(pK22) and HB101(pK23) recombinant strains as described in Example 6 were
20 respectively inoculated in 10 ml of LB medium and cultured at 37°C overnight. Fifty grams of Sawara sieved sand (unsterilized) were placed in 68 ml vials each. Five ml of LB medium inoculated with the above seed culture to 100:1, was then added to the sand.
25 Each vial was cotton-plugged, and incubated at 37°C for

4 hours without shaking. Then 1 ml of a 10 mM IPTG solution was added to each vial. After that, each vial was tightly sealed with a Teflon-coated butyl rubber stopper and aluminum seal. Gaseous TCE was introduced into the vials with a syringe to 20 ppm (supposing all TCE dissolved into the aqueous phase in the vial). The vials were incubated at 30°C. Quantitative analysis of TCE in the gas phase were carried out by gas chromatography after 6 hours to determine TCE concentrations. The results are shown in Table 9. E.coli HB101(pSE280) was employed as a control and evaluated in the same manner.

[Table 9]

	pK22	pK23	pSE280
TCE	0	0	20.3

(Unit: ppm)

The above results confirm that E.coli HB101 transformants harboring pK22 and pK23 also show an excellent TCE-degrading ability in soil. It is shown that transformant harboring pK23 (pSE380-based) expresses higher degrading activity with IPTG induction.

<Example 11>

-TCE Degradation by E.coli HB101(pK22) or HB101(pK23)
in Gas Phase (Without IPTG Induction)-

The cells of respective recombinant strains,
5 E.coli HB101(pK22) and HB101(pK23) as described in
Example 6, were inoculated in 100 ml of LB medium and
cultured at 37°C overnight. Aliquots (30 ml) of each
seed culture were transferred into 68 ml vials, into
which air which had passed through a saturation TCE
10 solution was introduced at a flow rate of 20 ml/min for
10 minutes. Each vial was tightly sealed with a
Teflon-coated butyl rubber stopper and aluminum seal,
and shaking culture was conducted at 30°C.
Quantitative analysis of TCE in the gas phase were
15 carried out by gas chromatography to determine its
concentration after 6 hours. The results are shown in
Table 10. E.coli HB101(pSE280) was employed as a
control and degradation was evaluated in the same
manner.

20

[Table 10]

	pK22	pK23	pSE280
TCE	0	12.1	47.9

25

(Unit: ppm)

The above results confirm that recombinant E.coli HB101(pK22) or HB101(pK23) shows an excellent TCE-degrading ability also in the gas phase. It is shown that transformant harboring pK23 (pSE380-based) expresses a lower degrading activity in a system not containing IPTG than that harboring pSE280-derived plasmid pK23, since the former contains lacIq.

<Example 12>

-TCE Degradation by recombinant E.coli HB101(pK22) and HB101(pK23) in Gas Phase (With IPTG Induction)-

E.coli (HB101) recombinant strains each harboring pK22 or pK23 as described in Example 6 were respectively inoculated into 100 ml of LB medium and cultured at 37°C to reach OD₆₀₀ of about 0.8, and then IPTG was added to 1 mM concentration followed by further incubation at 37°C for 5 hours. Aliquots (30 ml) of the cell suspension were transferred into 68 ml vials, into which air which had passed through in a saturated TCE solution was introduced at a flow rate of 20 ml/min for 10 minutes. Each vial was tightly sealed with a Teflon-coated butyl rubber stopper and aluminum seal, and shaking culture was conducted at 30°C. Quantitative analysis of TCE in the gas phase were carried out by gas chromatography to determine its concentration after 6 hours. The results are shown in Table 11. E.coli HB101(pSE280) was employed as a

control and degradation was evaluated in the same manner.

[Table 11]

	pK22	pK23	pSE280
TCE	0	0	54.2

(Unit: ppm)

The above results confirm that recombinant E.coli HB101(pK22) or HB101(pK23) shows an excellent TCE-degrading ability also in the gas phase, and show that transformant harboring pK23 (pSE380-based) expresses higher degrading activity with IPTG induction.

<Example 13>

-Introduction of Recombinant Plasmid containing Toluene Monooxygenase Gene into Vibrio sp. strain KB1-

The toluene monooxygenase gene beginning from the second ATG of tomK (base number 234-236) was transferred from the recombinant plasmid pK29 of Example 6 (recombinant pTrc99A containing the gene) into a vector pBBR122 (Mo Bi Tec) having a wide host range replication region not belonging to an incompatible group of IncP, IncQ, and IncW. This

recombinant plasmid was introduced in *Vibrio* sp. strain KB1, and its ability to degrade aromatic compounds and chlorinated aliphatic hydrocarbon compounds was evaluated.

5 First, a wide host range recombinant plasmid was constructed. An about 7.0-kb fragment containing the toluene monooxygenase gene, a *trc* promoter, and a *rrnB* terminator was cut out from pK29 using the restriction enzymes *HpaI* (Takara Shuzo Co., Ltd.) and *SmaI* (Takara
10 Shuzo Co., Ltd.). This fragment of about 7.0 kb does not contain the *lacIq* sequence. As a vector of a wide host range, pBBR122 was employed. pBBR122 was completely digested with the restriction enzyme *SmaI* (Takara Shuzo Co., Ltd.). The 7.0 kb fragment
15 containing the toluene monooxygenase gene, a *trc* promoter, and an *rrnB* terminator prepared as described above was ligated to the *SmaI* restriction site of the pBBR122 using DNA Ligation Kit Ver. 2 (Takara Shuzo Co., Ltd.) and the recombinant plasmid thus constructed
20 was introduced into *E.coli* HB101 (Takara Shuzo Co., Ltd.). The cells of the *E.coli* thus treated were applied on LB plate containing 50 µg/ml of chloramphenicol as a selection agent. When the colonies on the plate grew to an appropriate size, the
25 colonies were transferred by replica printing onto an LB plate containing 50 µg/ml of kanamycin as a selection agent. Transformants that could proliferate

on the plate with chloramphenicol but not on the plate with kanamycin were selected, and cultured in LB medium at 37°C overnight, to extract plasmid DNA from the cells by the alkaline method. After checking the plasmids, transformants harboring a recombinant plasmid where the 7.0 kb fragment was correctly inserted into the SmaI site of the pBBR122 were obtained. The recombinant plasmid thus obtained was about 12.3 kb in length and designated as pK29bbr.

10 The SOB medium shown below was employed for liquid culture of Vibrio sp. strain KB1. Chloramphenicol was used at a concentration of 50 µg/ml as a selection agent and the culture temperature was 30°C. The recombinant plasmid pK29 was introduced into Vibrio sp. strain KB1 cells by electroporation using a gene pulsar (Bio-Rad). The recombinant plasmid pK29bbr was stably retained after introduction into Vibrio sp. strain KB1.

15 SOB medium:

20 Trypton: 20 g
 Yeast extract: 5 g
 NaCl: 0.5 g
 250 mM KCl: 10 ml
 Distilled water (to 990 ml)
 pH 7.0

25 The above solution was sterilized by autoclaving and cooled to room temperature, to which 10 ml of a 2 M Mg solution (1 M MgSO₄·7H₂O + 1 M MgCl₂·6H₂O) separately

sterilized by autoclaving was added.

<Example 14>

-Ability of Vibrio sp. KB1(pK29bbr) to Degrade Aromatic
5 Compounds and Chlorinated Aliphatic Hydrocarbon
Compounds-

The cells of Vibrio sp. KB1(pK29bbr) were
inoculated in 100 ml of SOB medium, cultured at 30°C
overnight, harvested, washed, and then suspended in 100
10 ml of M9 (containing 6.2 g of Na₂HPO₄, 3.0 g of KH₂PO₄,
0.5 g of NaCl, and 1.0 g of NH₄Cl per liter)
supplemented with a mineral stock solution (3 ml to 1
liter of M9 medium).

Ten ml of the suspension was placed in respective
15 27.5 ml vials and each vial was tightly sealed with a
Teflon-coated butyl rubber stopper and aluminum seal.
Then, gaseous trichloroethylene (TCE), cis-1,2-
dichloroethylene (cis-1,2-DCE), trans-1,2-
dichloroethylene (trans-1,2-DCE), 1,1-dichloroethylene
20 (1,1-DCE), toluene, and benzene were added to
respective vials with a syringe to a concentration of
20 ppm (supposing all of the introduced substance
dissolved in the aqueous phase in the vial). The vials
were shaken and incubated at 30°C. The concentrations
25 of the respective compounds in the gas phase after 6
hour incubation were measured by gas chromatography.
The results are shown in Table 12. Vibrio sp.

KB1(pBBR122) was tested as a control and degradation was evaluated in the same manner.

[Table 12]

5		KB1(pK29bbr)	KB1(pBBR122)
	TCE	0	19.1
	cis-1,2-DCE	0	20.2
	trans-1,2-DCE	0	21.3
	1-1,DCE	0	19.2
10	Toluene	0	19.8
	Benzene	0	21.0

(Unit: ppm)

15 Similarly, to 10 ml of the prepared cell
suspension in a 27.5-ml vial, phenol, ortho-cresol,
meta-cresol, and para-cresol were added to 50 ppm,
respectively. The vial was tightly sealed with a butyl
rubber stopper and aluminum seal, and then shaken and
20 incubated at 30°C. The quantities of the respective
compounds in the liquid phase were measured by the
amino antipyrine method with a spectrophotometer to
obtain their concentrations after 6 hours. The results
are shown in Table 13. Vibrio species strain KB1
25 containing only pBBR122 was employed as a control and

degradation was evaluated in a similar system.

Similarly, phenol, ortho-cresol, meta-cresol and para-cresol were introduced at a concentration of 50 ppm into respective 27.5 ml vials each containing 10 ml of the cell suspension. Each vial was tightly sealed with a butyl rubber stopper and aluminum seal, and shaken and incubated at 30°C. The quantities of the respective compounds in the liquid phase were determined by the amino antipyrine method using a spectrophotometer to determine their concentrations after 6 hours. The results are shown in Table 13. Vibrio sp. KB1(pBBR122) was tested as a control and degradation was evaluated in the same manner.

[Table 13]

	KB1(pK29bbr)	KB1(pBBR122)
Phenol	0	51
Ortho-cresol	0	50
Meta-cresol	0	49
Para-cresol	0	50

(Unit: ppm)

The above results show that the recombinant Vibrio

sp. strain KB1 harboring pK29bbr can constitutively express the ability to degrade aromatic compounds and chlorinated aliphatic hydrocarbon compounds.

5 <Example 15>

-Degradation of TCE by Recombinant *Vibrio* sp.

KB1(pK29bbr) in Soil-

10 Vibrio sp. KB1(pK29bbr) recombinant strain as described in Example 13 was inoculated in 10 ml of SOB medium and cultured at 30°C overnight. Fifty grams of Sawara sieved sand (unsterilized) was placed in each 68 ml vial. Five ml of SOB medium inoculated with the above seed culture to 100:1 was then added to the sand in each vial. Each vial was cotton-plugged and
15 incubated at 30°C for 12 hours without shaking. After that, each vial was tightly sealed with a Teflon-coated butyl rubber stopper and aluminum seal. Gaseous TCE was introduced into the vials with a syringe to 20 ppm (supposing all TCE dissolved into the aqueous phase in
20 the vial). The vials were incubated at 30°C. Quantitative analysis of TCE in the gas phase were carried out by gas chromatography after 6 hours to determine TCE concentrations. The results are shown in Table 14. Vibrio sp. KB1(pBBR122) was tested as a
25 control and degradation was evaluated in the same manner.

[Table 14]

	KB1(pK29bbr)	KB1(pBBR122)
TCE	0	20.2

5 (Unit: ppm)

The above results show that the recombinant Vibrio sp. KB1(pK29bbr) can constitutively express the ability to degrade TCE also in soil.

10

<Example 16>

-Degradation of TCE by Recombinant Vibrio sp.

KB1(pK29bbr) in Gas Phase-

15 The cells of recombinant Vibrio sp. KB1(pK29bbr) as described in Example 13 were inoculated in 100 ml of SOB medium and cultured at 30°C overnight. Aliquots (30 ml) of the seed culture were transferred into 68 ml vials, into which air which had passed through a saturation TCE solution was introduced at a flow rate
20 of 20 ml/min for 10 minutes. Each vial was tightly sealed with a Teflon-coated butyl rubber stopper and aluminum seal, and shaking culture was conducted at 30°C. Quantitative analysis of TCE in the gas phase were carried out by gas chromatography to determine its
25 concentration after 6 hours. The results are shown in Table 15. Vibrio sp. KB1(pBBR122) was employed as a

control and degradation was evaluated in the same manner.

[Table 15]

5		KB1(pK29bbr)	KB1(pBBR122)
	TCE	0	52.1

(Unit: ppm)

10 The above results show that the recombinant Vibrio sp. KB1(pK29bbr) can constitutively express the ability to degrade TCE also in the gas phase.

15 According to the present invention, a DNA fragment carrying a toluene monooxygenase gene with an excellent ability to degrade aromatic compounds and chlorinated aliphatic hydrocarbon compounds can be obtained. In addition, a novel recombinant plasmid containing the DNA fragment as a whole or a part thereof that can be
20 utilized to obtain a transformant capable of degrading aromatic compounds and/or chlorinated aliphatic hydrocarbon compounds can be obtained. Further, a transformant harboring the plasmid and can be utilized to degrade aromatic compounds and/or chlorinated
25 aliphatic hydrocarbon compounds can be obtained. Furthermore, a practical method for environmental

[illegible]

SEQUENCE LISTING

<110> Yano, Tetsuya; Nomoto, Tsuyoshi; Imamura, Takeshi; Canon Kabushiki Kaisha
<120> DNA Fragment Carrying Toluene Monooxygenase Gene, Recombinant Plasmid,
Transformed Microorganism, Method for Degrading Chlorinated Aliphatic Hydrocarbon
Compounds and Aromatic Compounds, and Method for Environmental Remediation
<130>
<140>
<150> JP/
<151> 1998-10-30
<160> 13
<210> 1
<211> 5828
<212> DNA
<213> Burkholderia cepacia
<220>
<221> CDS
<222> 234..443
<223> tomK
<221> CDS
<222> 462...1455
<223> tomL
<221> CDS
<222> 1495...1761
<223> tomM
<221> CDS
<222> 1803...3350
<223> tomN
<221> CDS
<222> 3428...3781
<223> tomO
<221> CDS
<222> 3810...4871
<223> tomP
<221> CDS
<222> 4876...5229
<223> tomQ
<400> 1

gatcatttca tcaaatgcgc tgcagcgggt tgctcaaatg atgaaaaagg ccaccggaca	60
tgggttttcgg cacgatcgcc ggcggggcgtt ttccgttctg gttaaccgcc attgtgggtc	120
gcgaaatttta acttcgcgtc agggcttttc ctgaattatc gagatttttt gctgcctggg	180
tcgaactgtgg cacggatgct gcattgaagt ccggcatgga ggcgacaccg atc	233
atg aat cag cac ccc acc gat ett tcc ccg ttc gat ccc ggc cgc aag	281
Met Asn Gln His Pro Thr Asp Leu Ser Pro Phe Asp Pro Gly Arg Lys	
5 10 15	
tgc gtc cgc gtg acc ggc acg aac gcg cgc ggc ttc gtc gaa ttc gag	329
Cys Val Arg Val Thr Gly Thr Asn Ala Arg Gly Phe Val Glu Phe Glu	
20 25 30	
ctg tcg atc ggc ggc gcg ccg gaa ctg tgc gtc gag ctg acg ttg tct	377
Leu Ser Ile Gly Gly Ala Pro Glu Leu Cys Val Glu Leu Thr Leu Ser	
35 40 45	
cct gcc gcc ttc gat gcg ttc tgc cgc gaa cag cag gtc acg cgg ctc	425
Pro Ala Ala Phe Asp Ala Phe Cys Arg Glu Gln Gln Val Thr Arg Leu	
50 55 60	
gac gtc gaa gcg aac cca	443
Asp Val Glu Ala Asn Pro	
65 70	
tgaccttgaggagcaagaa	462
gtg acc atc gag ctg aag aca gtc gac atc aag ccg ctc cgg cac acc	510
Met Thr Ile Glu Leu Lys Thr Val Asp Ile Lys Pro Leu Arg His Thr	
5 10 15	
ttt gcg cat gtc gcg cag aac atc ggc ggc gac aag acg gcg acg cgc	558
Phe Ala His Val Ala Gln Asn Ile Gly Gly Asp Lys Thr Ala Thr Arg	
20 25 30	
tac cag gaa ggc atg atg ggc gcg cag ccc cag gag aac ttc cat tac	606
Tyr Gln Glu Gly Met Met Gly Ala Gln Pro Gln Glu Asn Phe His Tyr	
35 40 45	
cgg ccg acc tgg gac ccg gac tac gag atc ttc gat ccg tcg cgc tcg	654
Arg Pro Thr Trp Asp Pro Asp Tyr Glu Ile Phe Asp Pro Ser Arg Ser	
50 55 60	
gcg atc cgg atg gcg aac tgg tac gcg ttg aag gat ccg cgc cag ttc	702
Ala Ile Arg Met Ala Asn Trp Tyr Ala Leu Lys Asp Pro Arg Gln Phe	
65 70 75 80	
tac tac gcg tcg tgg gcg acc acg cgg gcg cgc cag cag gat gcg atg	750
Tyr Tyr Ala Ser Trp Ala Thr Thr Arg Ala Arg Gln Gln Asp Ala Met	

85	90	95	
gag tgc aac ttc gag ttc gtc gaa tgc cgc cgg atg atc ggc ctg atg			798
Glu Ser Asn Phe Glu Phe Val Glu Ser Arg Arg Met Ile Gly Leu Met			
100	105	110	
cgc gac gac gtg gcc gcg cgg gcg ctc gac gtg ctg gtg ccg ctg cgc			846
Arg Asp Asp Val Ala Ala Arg Ala Leu Asp Val Leu Val Pro Leu Arg			
115	120	125	
cac gcc gcg tgg ggc gcg aac atg aac aac gcg cag atc tgc gcg ctc			894
His Ala Ala Trp Gly Ala Asn Met Asn Asn Ala Gln Ile Cys Ala Leu			
130	135	140	
ggc tac ggc acg gtg ttc acc gcg ccc gcg atg ttc cat gcg atg gac			942
Gly Tyr Gly Thr Val Phe Thr Ala Pro Ala Met Phe His Ala Met Asp			
145	150	155	160
aac ctc ggc gtc gcg caa tac ctc acg cgt ctc gcg ctc gcg atg gcc			990
Asn Leu Gly Val Ala Gln Tyr Leu Thr Arg Leu Ala Leu Ala Met Ala			
165	170	175	
gag ccc gac gtg ctg gag gcg gcc aag gcg acc tgg acc cgc gac gcc			1038
Glu Pro Asp Val Leu Glu Ala Ala Lys Ala Thr Trp Thr Arg Asp Ala			
180	185	190	
gcc tgg cag ccg ctg cgc cgc tac gtc gag gac acg ctg gtc gtc gcc			1086
Ala Trp Gln Pro Leu Arg Arg Tyr Val Glu Asp Thr Leu Val Val Ala			
195	200	205	
gat ccg gtc gag ctg ttc atc gcg cag aac ctc gcg ctc gac ggc ctg			1134
Asp Pro Val Glu Leu Phe Ile Ala Gln Asn Leu Ala Leu Asp Gly Leu			
210	215	220	
ctg tat ccg ctc gtc tac gac cgc ttc gtc gac gaa cgg atc gcg ctc			1182
Leu Tyr Pro Leu Val Tyr Asp Arg Phe Val Asp Glu Arg Ile Ala Leu			
225	230	235	240
gaa ggc ggc tgc gca gtc gcg atg ctg acc gcg ttc atg ccc gaa tgg			1230
Glu Gly Gly Ser Ala Val Ala Met Leu Thr Ala Phe Met Pro Glu Trp			
245	250	255	
cac acc gag tgc aac cgc tgg atc gac gcg gtc gtg aag acg atg gcc			1278
His Thr Glu Ser Asn Arg Trp Ile Asp Ala Val Val Lys Thr Met Ala			
260	265	270	
gcc gaa tcc gac gac aac cgc gcg ctg ctc gcc cgc tgg aca cgc gac			1326
Ala Glu Ser Asp Asp Asn Arg Ala Leu Leu Ala Arg Trp Thr Arg Asp			
275	280	285	

tgg tcc gcg cgc gcc gag gcg gca ctg gca ccg gtg gcg gca cgc gcg 1374
 Trp Ser Ala Arg Ala Glu Ala Ala Leu Ala Pro Val Ala Ala Arg Ala
 290 295 300
 ctg cag gat gcc ggg cgc gcg gcg ctc gac gaa gtg cgc gag cag ttc 1422
 Leu Gln Asp Ala Gly Arg Ala Ala Leu Asp Glu Val Arg Glu Gln Phe
 305 310 315 320
 cac gca cgc gcg gcc agg ctc gcc atc gcg ctc 1455
 His Ala Arg Ala Ala Arg Leu Gly Ile Ala Leu
 325 330
 tgacgacggg aatcctccct taacccaagg aatgccagc 1494
 atg tcc aac gta ttc atc gcc ttt cag gcc aat gag gac tcc aga ccg 1542
 Met Ser Asn Val Phe Ile Ala Phe Gln Ala Asn Glu Asp Ser Arg Pro
 5 10 15
 atc gtg gat gcg atc gtc gcc gac aac ccg cgc gcg gtg gtg gtc gag 1590
 Ile Val Asp Ala Ile Val Ala Asp Asn Pro Arg Ala Val Val Val Glu
 20 25 30
 tcg ccc ggc atg gtc aag atc gac gcg ccg gac cgg ctg acg atc cgc 1638
 Ser Pro Gly Met Val Lys Ile Asp Ala Pro Asp Arg Leu Thr Ile Arg
 35 40 45
 cgc gaa acg atc gag gaa ctg acc gcc acg cgc ttc gac ctg cag cag 1686
 Arg Glu Thr Ile Glu Glu Leu Thr Gly Thr Arg Phe Asp Leu Gln Gln
 50 55 60
 ctc cag gtc aac ctg atc acg ctg tca ggc cac atc gac gag gac gac 1734
 Leu Gln Val Asn Leu Ile Thr Leu Ser Gly His Ile Asp Glu Asp Asp
 65 70 75 80
 gac gag ttc acg ctg agc tgg tcg cac 1761
 Asp Glu Phe Thr Leu Ser Trp Ser His
 85
 tgaacgccgc gccacgcgca ccgacaacac cggagacacg a 1802
 atg gac acg cca acg ctc aag aaa aaa ctc gcc ctg aag gac cgc tac 1850
 Met Asp Thr Pro Thr Leu Lys Lys Lys Leu Gly Leu Lys Asp Arg Tyr
 5 10 15
 gcg gca atg acg cgc gcc ctc gcc tgg gag acg acc tac cag ccg atg 1898
 Ala Ala Met Thr Arg Gly Leu Gly Trp Glu Thr Thr Tyr Gln Pro Met
 20 25 30
 gac aag gtc ttc ccg tac gac cgc tac gag gcc atc aag atc cac gac 1946
 Asp Lys Val Phe Pro Tyr Asp Arg Tyr Glu Gly Ile Lys Ile His Asp

35	40	45	
tgg gac aag tgg gtc gac ccg ttc cgc ctg acg atg gat gcg tac tgg	1994		
Trp Asp Lys Trp Val Asp Pro Phe Arg Leu Thr Met Asp Ala Tyr Trp			
50	55	60	
aaa tac cag ggc gag aag gaa aag aag ctg tac gcg gtg atc gac gcg	2042		
Lys Tyr Gln Gly Glu Lys Glu Lys Lys Leu Tyr Ala Val Ile Asp Ala			
65	70	75	80
ttc acg cag aac aac gcg ttc ctc ggc gtg agc gac gcc cgc tac atc	2090		
Phe Thr Gln Asn Asn Ala Phe Leu Gly Val Ser Asp Ala Arg Tyr Ile			
85	90	95	
aac gcg ctg aag ctg ttc ctc cag ggc gtg acg ccg ctc gaa tac ctc	2138		
Asn Ala Leu Lys Leu Phe Leu Gln Gly Val Thr Pro Leu Glu Tyr Leu			
100	105	110	
gcg cac cgc ggc ttc gcg cat gtc ggc cgg cac ttc acc ggc gag ggc	2186		
Ala His Arg Gly Phe Ala His Val Gly Arg His Phe Thr Gly Glu Gly			
115	120	125	
gcg cgc atc gcg tgc cag atg cag tcg atc gac gag ctg cgg cac tac	2234		
Ala Arg Ile Ala Cys Gln Met Gln Ser Ile Asp Glu Leu Arg His Tyr			
130	135	140	
cag acc gaa acg cat gcg atg tcg acg tac aac aag ttc ttc aac ggg	2282		
Gln Thr Glu Thr His Ala Met Ser Thr Tyr Asn Lys Phe Phe Asn Gly			
145	150	155	160
ttc cat cac tcg aac cag tgg ttc gac cgc gtg tgg tac ctg tcg gtg	2330		
Phe His His Ser Asn Gln Trp Phe Asp Arg Val Trp Tyr Leu Ser Val			
165	170	175	
ccg aag tcg ttc ttc gag gac gcg tat tcg tcg ggg ccg ttc gag ttc	2378		
Pro Lys Ser Phe Phe Glu Asp Ala Tyr Ser Ser Gly Pro Phe Glu Phe			
180	185	190	
ctg acc gcg gtc agc ttc tcg ttc gaa tac gtg ctg acg aac ctg ctg	2426		
Leu Thr Ala Val Ser Phe Ser Phe Glu Tyr Val Leu Thr Asn Leu Leu			
195	200	205	
ttc gtg ccg ttc atg tcg ggc gcc gcc tac aac ggt gac atg tcg acc	2474		
Phe Val Pro Phe Met Ser Gly Ala Ala Tyr Asn Gly Asp Met Ser Thr			
210	215	220	
gtc acg ttc ggc ttc tcc gcg cag tcg gac gaa tcg cgt cac atg acg	2522		
Val Thr Phe Gly Phe Ser Ala Gln Ser Asp Glu Ser Arg His Met Thr			
225	230	235	240

ctc	ggc	atc	gaa	tgc	atc	aag	ttc	ctg	ctc	gaa	cag	gac	ccg	gac	aac	2570
Leu	Gly	Ile	Glu	Cys	Ile	Lys	Phe	Leu	Leu	Glu	Gln	Asp	Pro	Asp	Asn	
245				250				255								
gtg	ccg	atc	gtg	cag	cgc	tgg	atc	gac	aag	tgg	ttc	tgg	cgc	ggc	tac	2618
Val	Pro	Ile	Val	Gln	Arg	Trp	Ile	Asp	Lys	Trp	Phe	Trp	Arg	Gly	Tyr	
260				265				270								
cgg	ctg	ctg	acg	ctg	gtc	gcg	atg	atg	atg	gac	tac	atg	cag	ccc	aag	2666
Arg	Leu	Leu	Thr	Leu	Val	Ala	Met	Met	Met	Asp	Tyr	Met	Gln	Pro	Lys	
275				280				285								
cgc	gtg	atg	agc	tgg	cgc	gag	tcg	tgg	gag	atg	tac	gcc	gag	cag	aac	2714
Arg	Val	Met	Ser	Trp	Arg	Glu	Ser	Trp	Glu	Met	Tyr	Ala	Glu	Gln	Asn	
290				295				300								
ggc	ggc	gcg	ctg	ttc	aag	gat	ctc	gcg	cgc	tac	ggc	att	cgc	gag	ccg	2762
Gly	Gly	Ala	Leu	Phe	Lys	Asp	Leu	Ala	Arg	Tyr	Gly	Ile	Arg	Glu	Pro	
305				310				315				320				
aag	ggc	tgg	cag	gac	gcc	tgc	gaa	ggc	aag	gat	cac	atc	agc	cac	cag	2810
Lys	Gly	Trp	Gln	Asp	Ala	Cys	Glu	Gly	Lys	Asp	His	Ile	Ser	His	Gln	
325				330				335								
gcg	tgg	tcg	acg	ttc	tac	ggc	ttc	aac	gcg	gcc	tcg	gcg	ttc	cac	acc	2858
Ala	Trp	Ser	Thr	Phe	Tyr	Gly	Phe	Asn	Ala	Ala	Ser	Ala	Phe	His	Thr	
340				345				350								
tgg	gtg	ccg	acc	gaa	gac	gaa	atg	ggc	tgg	ctg	tcg	gcg	aag	tat	ccc	2906
Trp	Val	Pro	Thr	Glu	Asp	Glu	Met	Gly	Trp	Leu	Ser	Ala	Lys	Tyr	Pro	
355				360				365								
gac	tcg	ttc	gac	cgc	tac	tac	cgc	ccg	cgc	ttc	gat	cac	tgg	ggc	gag	2954
Asp	Ser	Phe	Asp	Arg	Tyr	Tyr	Arg	Pro	Arg	Phe	Asp	His	Trp	Gly	Glu	
370				375				380								
cag	gcc	agg	gcc	ggc	aac	cgc	ttc	tac	atg	aag	acg	ctg	ccg	atg	ctg	3002
Gln	Ala	Arg	Ala	Gly	Asn	Arg	Phe	Tyr	Met	Lys	Thr	Leu	Pro	Met	Leu	
385				390				395				400				
tgc	cag	acg	tgc	cag	atc	ccg	atg	ctg	ttc	acc	gag	ccg	ggc	aac	ccg	3050
Cys	Gln	Thr	Cys	Gln	Ile	Pro	Met	Leu	Phe	Thr	Glu	Pro	Gly	Asn	Pro	
405				410				415								
acg	aag	atc	ggc	gcg	cgc	gaa	tcg	aac	tac	ctc	ggc	aac	aag	ttc	cac	3098
Thr	Lys	Ile	Gly	Ala	Arg	Glu	Ser	Asn	Tyr	Leu	Gly	Asn	Lys	Phe	His	
420				425				430								
ttc	tgc	agc	gac	cac	tgc	aag	gac	atc	ttc	gat	cac	gag	ccg	cag	aaa	3148

Phe Cys Ser Asp His Cys Lys Asp Ile Phe Asp His Glu Pro Gln Lys
435 440 445
tac gtg cag gcg tgg ctg ccg gtg cac cag atc cat cag ggc aac tgc 3194
Tyr Val Gln Ala Trp Leu Pro Val His Gln Ile His Gln Gly Asn Cys
450 455 460
ttc ccg ccc gat gcg gac ccg ggc gcg gag ggc ttc gat ccg ctc gcc 3242
Phe Pro Pro Asp Ala Asp Pro Gly Ala Glu Gly Phe Asp Pro Leu Ala
465 470 475 480
gcg gtg ctc gac tac tac gcg gtg acg atg ggc cgc gac aac ctc gat 3290
Ala Val Leu Asp Tyr Tyr Ala Val Thr Met Gly Arg Asp Asn Leu Asp
485 490 495
ttc gac ggc tgc gaa gac cag aag aac ttc gcg gcg tgg cgc ggc cag 3338
Phe Asp Gly Ser Glu Asp Gln Lys Asn Phe Ala Ala Trp Arg Gly Gln
500 505 510
gcc acg cgc aac 3350
Ala Thr Arg Asn
515
tgaccgcgcaa cgacaagcaa tcttgacgag ggcccgcgaa gcgccgatgc gcgaacgcgg 3410
gccgacagga gacaaac 3427
atg gcc gtc atc gcg ctc aaa ccc tac gac ttc ccg gtg aag gat gcc 3475
Met Ala Val Ile Ala Leu Lys Pro Tyr Asp Phe Pro Val Lys Asp Ala
5 10 15
gtc gag aag ttt ccg gcg ccg ctg ctc tac gtg tgc tgg gaa aac cat 3523
Val Glu Lys Phe Pro Ala Pro Leu Leu Tyr Val Cys Trp Glu Asn His
20 25 30
ctg atg ttc ccg gcg ccg ttc tgc ctg ccg ctg ccg ccc gac atg ccg 3571
Leu Met Phe Pro Ala Pro Phe Cys Leu Pro Leu Pro Pro Asp Met Pro
35 40 45
ttc ggc gcg ctg gcc ggc gac gtg ctg ccg ccc gtc tac ggc tat cac 3619
Phe Gly Ala Leu Ala Gly Asp Val Leu Pro Pro Val Tyr Gly Tyr His
50 55 60
ccc gac ttc gcg aag atc gac tgg gat cgc gtc gag tgg ttc cgg tgc 3667
Pro Asp Phe Ala Lys Ile Asp Trp Asp Arg Val Glu Trp Phe Arg Ser
65 70 75 80
ggc gag ccg tgg gcg ccg gac ccg gcg aag agc ctg gcc ggc aac ggc 3715
Gly Glu Pro Trp Ala Pro Asp Pro Ala Lys Ser Leu Ala Gly Asn Gly
85 90 95

ctc ggg cac aag gac ctg atc agc ttc cgc acg ccc ggc ctc gac ggc 3763
 Leu Gly His Lys Asp Leu Ile Ser Phe Arg Thr Pro Gly Leu Asp gly
 100 105 110

ctc ggc ggc gcg agc ttc 3781
 Leu Gly Gly Ala Ser Phe
 115

tgaccgccac gcggacgagc gaaccatc 3809
 atg agc cac caa ctt acc atc gag ccg ctg ggc gtc acg atc gag gtc 3857
 Met Ser His Gln Leu Thr Ile Glu Pro Leu Gly Val Thr Ile Glu Val
 5 10 15

gag gaa gga cag acg atg ctc gat gcc gcg ctg cgc cag ggc atc tac 3905
 Glu Glu Gly Gln Thr Met Leu Asp Ala Ala Leu Arg Gln Gly Ile Tyr
 20 25 30

att ccg cac gcg tgc tgt cac ggg ctg tgc ggc acc tgc aag gtc gcc 3953
 Ile Pro His Ala Cys Cys His Gly Leu Cys Gly Thr Cys Lys Val Ala
 35 40 45

gtg ctc gac ggc gag acc gat ccc ggc gat gcg aac ccg ttc gcg ctg 4001
 Val Leu Asp Gly Glu Thr Asp Pro Gly Asp Ala Asn Pro Phe Ala Leu
 50 55 60

atg gat ttc gag cgc gag gaa ggc aag gcg ctc gcg tgc tgc gcg acg 4049
 Met Asp Phe Glu Arg Glu Glu Gly Lys Ala Leu Ala Cys Cys Ala Thr
 65 70 75 80

ctg cag gcc gac acc gtg atc gag gcc gac gtc gac gag gag ccg gat 4097
 Leu Gln Ala Asp Thr Val Ile Glu Ala Asp Val Asp Glu Glu Pro Asp
 85 90 95

gcg gaa atc atc ccg gtc agg gac ttc gcg gcc gac gtc acg cgc atc 4145
 Ala Glu Ile Ile Pro Val Arg Asp Phe Ala Ala Asp Val Thr Arg Ile
 100 105 110

gaa cag ctc acg ccg acc atc aag tcg atc cgc ctg aag ctg tcg cag 4193
 Glu Gln Leu Thr Pro Thr Ile Lys Ser Ile Arg Leu Lys Leu Ser Gln
 115 120 125

ccg atc cgc ttc cag gcg ggc cag tac gtg cag ctc gag att ccc ggc 4241
 Pro Ile Arg Phe Gln Ala Gly Gln Tyr Val Gln Leu Glu Ile Pro Gly
 130 135 140

ctc ggg cag agc cgc gcg ttc tcg atc gcg aac gcg ccg gcc gac gtc 4289
 Leu Gly Gln Ser Arg Ala Phe Ser Ile Ala Asn Ala Pro Ala Asp Val
 145 150 155 160

gcg gcc acc ggc gag atc gaa ctg aac gtg cgg cag gtg ccg ggc ggg 4337
Ala Ala Thr Gly Glu Ile Glu Leu Asn Val Arg Gln Val Pro Gly Gly
165 170 175
ctc ggc acg ggc tac ctg cac gag caa ctg gcg acg ggc gag cgc gtg 4385
Leu Gly Thr Gly RTr Leu His Glu Gln Leu Ala Thr Gly Glu Arg Val
180 185 190
cgc ctg tcg ggc ccg tac ggc cgc ttc ttc gtg cgt cgc tcg gcc gcg 4433
Arg Leu Ser Gly Pro Tyr Gly Arg Phe Phe Val Arg Arg Ser Ala Ala
195 200 205
cgg ccg atg atc ttc atg gcc ggc ggg tcg ggg ctg tcg agc ccg cgc 4481
arg Pro Met Ile Phe Met ala gly gly Ser gly Leu Ser Ser Pro arg
210 215 220
tcg atg atc gcg gac ctg ctc gca agc ggc gtc acc gcg ccg atc acg 4529
Ser Met Ile ala asp Leu Leu ala Ser gly Val thr ala Pro Ile thr
225 230 235 240
ctg gtc tac ggt cag cgc agc gcg cag gag ctc tac tac cac gac gaa 4577
Leu Val tyr gly gln arg Ser ala gln glu Leu tyr tyr His asp glu
245 250 255
ttc cgc gcg ctg gcc gaa cgc cat ccg aac ttc acg tac gtg ccg gcg 4625
Phe arg ala Leu ala glu arg His Pro asn Phe thr tyr Val Pro ala
260 265 270
ctg tcc gaa ggc gca ccg cac gcg ggc ggc gac gtc gcg caa ggg ttc 4673
Leu Ser Glu Gly Ala Pro His Ala Gly Gly Asp Val Ala Gln Gly Phe
275 280 285
gtg cac gac gtc gcg aag gca cat ttc ggc ggc gac ttc tcc ggg cac 4721
Val His Asp Val Ala Lys Ala His Phe Gly Gly Asp Phe Ser Gly His
290 295 300
cag gcg tac ctg tgc ggg ccg ccc gcg atg atc gac gcg tgc atc acg 4769
Gln Ala Tyr Leu Cys Gly Pro Pro Ala Met Ile Asp Ala Cys Ile Thr
305 310 315 320
acg ctg atg cag ggg cgc ctg ttc gag cgc gac atc tat cac gag aag 4817
Thr Leu Met Gln Gly Arg Leu Phe Glu Arg Asp Ile Tyr His Glu Lys
325 330 335
ttc atc tcg gcg gcc gac gcg caa cag acg cgc agc ccg ctg ttc cgg 4865
Phe Ile Ser Ala Ala Asp Ala Gln Gln Thr Arg Ser Pro Leu Phe Arg
340 345 350
cgg gtg 4871

Arg Val

tgac 4875

atg gac gcg ggc cgc gta tgc ggg acg gtc acg atc gcg cag acc gac 4923

Met Asp Ala Gly Arg Val Cys Gly Thr Val Thr Ile Ala Gln Thr Asp

5 10 15

gag cgc tat gcg tgc gtg tcc ggc gag tcg ctg ctg gcc ggc atg gcg 4971

Glu Arg Tyr Ala Cys Val Ser Gly Glu Ser Leu Leu Ala Gly Met Ala

20 25 30

aaa ctc ggc cgg cgc ggc att ccg gtc ggc tgc ctg aac ggc ggg tgc 5019

Lys Leu Gly Arg Arg Gly Ile Pro Val Gly Cys Leu Asn Gly Gly Cys

35 40 45

ggc gtg tgc aag gtg cgc gtg ctg cgc ggt gcg gtg cgc aag ctc ggc 5067

Gly Val Cys Lys Val Arg Val Leu Arg Gly Ala Val Arg Lys Leu Gly

50 55 60

ccg atc agc cgt gcc cat gtg agc gcg gaa gaa gag aac gac ggc tac 5115

Pro Ile Ser Arg Ala His Val Ser Ala Glu Glu Glu Asn Asp Gly Tyr

65 70 75 80

gcg ctt gcg tgc cgc gtc gtg ccg gac ggc gac gtc gaa ctc gaa gtg 5163

Ala Leu Ala Cys Arg Val Val Pro Asp Gly Asp Val Glu Leu Glu Val

85 90 95

gcc ggc cgg ctc agg aag ccg ttc ttc tgc ggc atg gca tgt gcc ggc 5211

Ala Gly Arg Leu Arg Lys Pro Phe Phe Cys Gly Met Ala Cys Ala Gly

100 105 110

acg gcg gcg atc aac aag 5229

Thr Ala Ala Ile Asn Lys

115

taaccaggag gagactcacc atgggtgtga tgcgtattgg tcatgtcagt ctgaagggtga 5289

tggacatgga agcggcgctg cgtcattacg tacgcgtgct cggcatgcag gaaacgatgc 5349

gcgacgcggc gggcaacgtc tacctgaaat gctgggacga atgggacaag tattcgtga 5409

tcctgtcgcc gtccgatcag gcggggctca agcatgccgc ctacaaggte gagcacgacg 5469

ccgatctgga tgcgctgcag cagcgcacgc aagcgtacgg gatcgcgacc gagatgctgc 5529

ccgaaggcgc gctgccggcg gtcggccgcc aactgcgggt cctgctgccg agcggccatg 5589

aactgcggct gttcgcgaag aaggcgctgg tgggcaccgc ggtcggctcg ctgaaccccg 5649

atccgtggcc cgacgacatt ccgggctcgg ccgtgcactg gctcgaccac tgcctgctga 5709

tgtgcgaact gaaccggag gccggcgta accgcgtga ggagaacacg cgcttcatgg 5769

ccgagtgtct cgacttccat ctggccgagc aggtgatggt cggcccgggc aacacgac 5828

<211> 76

<212> PRT

<213> Burkholderia cepacia

<220>

<223> TomK polypeptide

<400> 2

Met Glu Ala Thr Pro Ile Met Asn Gln His Pro Thr Asp Leu Ser Pro

5 10 15

Phe Asp Pro Gly Arg Lys Cys Val Arg Val Thr Gly Thr Asn Ala Arg

20 25 30

Gly Phe Val Glu Phe Glu Leu Ser Ile Gly Gly Ala Pro Glu Leu Cys

35 40 45

Val Glu Leu Thr Leu Ser Pro Ala Ala Phe Asp Ala Phe Cys Arg Glu

50 55 60

Gln Gln Val Thr Arg Leu Asp Val Glu Ala Asn Pro

65 70 75

<210> 3

<211> 355

<212> PRT

<213> Burkholderia cepacia

<220>

<223> TomL polypeptide

<400> 3

Met Arg Ser Ala Ala Asn Ser Arg Ser Arg Gly Ser Thr Ser Lys Arg

5 10 15

Thr His Asp Leu Glu Glu Gln Glu Val Thr Ile Glu Leu Lys Thr Val

20 25 30

Asp Ile Lys Pro Leu Arg His Thr Phe Ala His Val Ala Gln Asn Ile

35 40 45

Gly Gly Asp Lys Thr Ala Thr Arg Tyr Gln Glu Gly Met Met Gly Ala

50 55 60

Gln Pro Gln Glu Asn Phe His Tyr Arg Pro Thr Trp Asp Pro Asp Tyr

65 70 75 80

Glu Ile Phe Asp Pro Ser Arg Ser Ala Ile Arg Met Ala Asn Trp Tyr

85 90 95

Ala Leu Lys Asp Pro Arg Gln Phe Tyr Tyr Ala Ser Trp Ala Thr Thr

100 105 110

Arg Ala Arg Gln Gln Asp Ala Met Glu Ser Asn Phe Glu Phe Val Glu
115 120 125
Ser Arg Arg Met Ile Gly Leu Met Arg Asp Asp Val Ala Ala Arg Ala
130 135 140
Leu Asp Val Leu Val Pro Leu Arg His Ala Ala Trp Gly Ala Asn Met
145 150 155 160
Asn Asn Ala Gln Ile Cys Ala Leu Gly Tyr Gly Thr Val Phe Thr Ala
165 170 175
Pro Ala Met Phe His Ala Met Asp Asn Leu Gly Val Ala Gln Tyr Leu
180 185 190
Thr Arg Leu Ala Leu Ala Met Ala Glu Pro Asp Val Leu Glu Ala Ala
195 200 205
Lys Ala Thr Trp Thr Arg Asp Ala Ala Trp Gln Pro Leu Arg Arg Tyr
210 215 220
Val Glu Asp Thr Leu Val Val Ala Asp Pro Val Glu Leu Phe Ile Ala
225 230 235 240
Gln Asn Leu Ala Leu Asp Gly Leu Leu Tyr Pro Leu Val Tyr Asp Arg
245 250 255
Phe Val Asp Glu Arg Ile Ala Leu Glu Gly Gly Ser Ala Val Ala Met
260 265 270
Leu Thr Ala Phe Met Pro Glu Trp His Thr Glu Ser Asn Arg Trp Ile
275 280 285
Asp Ala Val Val Lys Thr Met Ala Ala Glu Ser Asp Asp Asn Arg Ala
290 295 300
Leu Leu Ala Arg Trp Thr Arg Asp Trp Ser Ala Arg Ala Glu Ala Ala
305 310 315 320
Leu Ala Pro Val Ala Ala Arg Ala Leu Gln Asp Ala Gly Arg Ala Ala
325 330 335
Leu Asp Glu Val Arg Glu Gln Phe His Ala Arg Ala Ala Arg Leu Gly
340 345 350
Ile Ala Leu
355
<210> 4
<211> 89
<212> PRT
<213> Burkholderia cepacia
<220>

<223> TomM polypeptide

<400> 4

```
Met Ser Asn Val Phe Ile Ala Phe Gln Ala Asn Glu Asp Ser Arg Pro
      5              10              15
Ile Val Asp Ala Ile Val Ala Asp Asn Pro Arg Ala Val Val Val Glu
      20              25              30
Ser Pro Gly Met Val Lys Ile Asp Ala Pro Asp Arg Leu Thr Ile Arg
      35              40              45
Arg Glu Thr Ile Glu Glu Leu Thr Gly Thr Arg Phe Asp Leu Gln Gln
      50              55              60
Leu Gln Val Asn Leu Ile Thr Leu Ser Gly His Ile Asp Glu Asp Asp
      65              70              75              80
Asp Glu Phe Thr Leu Ser Trp Ser His
```

85

<210> 5

<211> 516

<212> PRT

<213> Burkholeria cepacia

<223> TomN polypeptide

<400> 5

```
Met Asp Thr Pro Thr Leu Lys Lys Lys Leu Gly Leu Lys Asp Arg Tyr
      5              10              15
Ala Ala Met Thr Arg Gly Leu Gly Trp Glu Thr Thr Tyr Gln Pro Met
      20              25              30
Asp Lys Val Phe Pro Tyr Asp Arg Tyr Glu Gly Ile Lys Ile His Asp
      35              40              45
Trp Asp Lys Trp Val Asp Pro Phe Arg Leu Thr Met Asp Ala Tyr Trp
      50              55              60
Lys Tyr Gln Gly Glu Lys Glu Lys Lys Leu Tyr Ala Val Ile Asp Ala
      65              70              75              80
Phe Thr Gln Asn Asn Ala Phe Leu Gly Val Ser Asp Ala Arg Tyr Ile
      85              90              95
Asn Ala Leu Lys Leu Phe Leu Gln Gly Val Thr Pro Leu Glu Tyr Leu
      100             105             110
Ala His Arg Gly Phe Ala His Val Gly Arg His Phe Thr Gly Glu Gly
      115             120             125
Ala Arg Ile Ala Cys Gln Met Gln Ser Ile Asp Glu Leu Arg His Tyr
```

130	135	140	
Gln Thr Glu Thr His Ala Met Ser Thr Tyr Asn Lys Phe Phe Asn Gly			
145	150	155	160
Phe His His Ser Asn Gln Trp Phe Asp Arg Val Trp Tyr Leu Ser Val			
	165	170	175
Pro Lys Ser Phe Phe Glu Asp Ala Tyr Ser Ser Gly Pro Phe Glu Phe			
	180	185	190
Leu Thr Ala Val Ser Phe Ser Phe Glu Tyr Val Leu Thr Asn Leu Leu			
	195	200	205
Phe Val Pro Phe Met Ser Gly Ala Ala Tyr Asn Gly Asp Met Ser Thr			
	210	215	220
Val Thr Phe Gly Phe Ser Ala Gln Ser Asp Glu Ser Arg His Met Thr			
	225	230	235
Leu Gly Ile Glu Cys Ile Lys Phe Leu Leu Glu Gln Asp Pro Asp Asn			
	245	250	255
Val Pro Ile Val Gln Arg Trp Ile Asp Lys Trp Phe Trp Arg Gly Tyr			
	260	265	270
Arg Leu Leu Thr Leu Val Ala Met Met Met Asp Tyr Met Gln Pro Lys			
	275	280	285
Arg Val Met Ser Trp Arg Glu Ser Trp Glu Met Tyr Ala Glu Gln Asn			
	290	295	300
Gly Gly Ala Leu Phe Lys Asp Leu Ala Arg Tyr Gly Ile Arg Glu Pro			
	305	310	315
Lys Gly Trp Gln Asp Ala Cys Glu Gly Lys Asp His Ile Ser His Gln			
	325	330	335
Ala Trp Ser Thr Phe Tyr Gly Phe Asn Ala Ala Ser Ala Phe His Thr			
	340	345	350
Trp Val Pro Thr Glu Asp Glu Met Gly Trp Leu Ser Ala Lys Tyr Pro			
	355	360	365
Asp Ser Phe Asp Arg Tyr Tyr Arg Pro Arg Phe Asp His Trp Gly Glu			
	370	375	380
Gln Ala Arg Ala Gly Asn Arg Phe Tyr Met Lys Thr Leu Pro Met Leu			
	385	390	395
Cys Gln Thr Cys Gln Ile Pro Met Leu Phe Thr Glu Pro Gly Asn Pro			
	405	410	415
Thr Lys Ile Gly Ala Arg Glu Ser Asn Tyr Leu Gly Asn Lys Phe His			
	420	425	430

Phe Cys Ser Asp His Cys Lys Asp Ile Phe Asp His Glu Pro Gln Lys
435 440 445

Tyr Val Gln Ala Trp Leu Pro Val His Gln Ile His Gln Gly Asn Cys
450 455 460

Phe Pro Pro Asp Ala Asp Pro Gly Ala Glu Gly Phe Asp Pro Leu Ala
465 470 475 480

Ala Val Leu Asp Tyr Tyr Ala Val Thr Met Gly Arg Asp Asn Leu Asp
485 490 495

Phe Asp Gly Ser Glu Asp Gln Lys Asn Phe Ala Ala Trp Arg Gly Gln
500 505 510

Ala Thr Arg Asn
515

<210> 6

<211> 118

<212> PRT

<213> Burkholderia cepacia

<220>

<223> TomO polypeptide

<400> 6

Met Ala Val Ile Ala Leu Lys Pro Tyr Asp Phe Pro Val Lys Asp Ala
5 10 15

Val Glu Lys Phe Pro Ala Pro Leu Leu Tyr Val Cys Trp Glu Asn His
20 25 30

Leu Met Phe Pro Ala Pro Phe Cys Leu Pro Leu Pro Pro Asp Met Pro
35 40 45

Phe Gly Ala Leu Ala Gly Asp Val Leu Pro Pro Val Tyr Gly Tyr His
50 55 60

Pro Asp Phe Ala Lys Ile Asp Trp Asp Arg Val Glu Trp Phe Arg Ser
65 70 75 80

Gly Glu Pro Trp Ala Pro Asp Pro Ala Lys Ser Leu Ala Gly Asn Gly
85 90 95

Leu Gly His Lys Asp Leu Ile Ser Phe Arg Thr Pro Gly Leu Asp Gly
100 105 110

Leu Gly Gly Ala Ser Phe
115

<210> 7

<211> 352

<212> PRT

<213> Burkholderia cepacia

<220>

<223> TomP polypeptide

<400> 7

```

Met Ser His Gln Leu Thr Ile Glu Pro Leu Gly Val Thr Ile Glu Val
      5              10              15
Glu Glu Gly Gln Thr Met Leu Asp Ala Ala Leu Arg Gln Gly Ile Tyr
      20              25              30
Ile Pro His Ala Cys Cys His Gly Leu Cys Gly Thr Cys Lys Val Ala
      35              40              45
Val Leu Asp Gly Glu Thr Asp Pro Gly Asp Ala Asn Pro Phe Ala Leu
      50              55              60
Met Asp Phe Glu Arg Glu Glu Gly Lys Ala Leu Ala Cys Cys Ala Thr
      65              70              75              80
Leu Gln Ala Asp Thr Val Ile Glu Ala Asp Val Asp Glu Glu Pro Asp
      85              90              95
Ala Glu Ile Ile Pro Val Arg Asp Phe Ala Ala Asp Val Thr Arg Ile
      100             105             110
Glu Gln Leu Thr Pro Thr Ile Lys Ser Ile Arg Leu Lys Leu Ser Gln
      115             120             125
Pro Ile Arg Phe Gln Ala Gly Gln Tyr Val Gln Leu Glu Ile Pro Gly
      130             135             140
Leu Gly Gln Ser Arg Ala Phe Ser Ile Ala Asn Ala Pro Ala Asp Val
      145             150             155             160
Ala Ala Thr Gly Glu Ile Glu Leu Asn Val Arg Gln Val Pro Gly Gly
      165             170             175
Leu Gly Thr Gly Tyr Leu His Glu Gln Leu Ala Thr Gly Glu Arg Val
      180             185             190
Arg Leu Ser Gly Pro Tyr Gly Arg Phe Phe Val Arg Arg Ser Ala Ala
      195             200             205
Arg Pro Met Ile Phe Met Ala Gly Gly Ser Gly Leu Ser Ser Pro Arg
      210             215             220
Ser Met Ile Ala Asp Leu Leu Ala Ser Gly Val Thr Ala Pro Ile Thr
      225             230             235             240
Leu Val Tyr Gly Gln Arg Ser Ala Gln Glu Leu Tyr Tyr His Asp Glu
      245             250             255

```

2025 RELEASE UNDER E.O. 14176

Phe Arg Ala Leu Ala Glu Arg His Pro Asn Phe Thr Tyr Val Pro Ala
 260 265 270
 Leu Ser Glu Gly Ala Pro His Ala Gly Gly Asp Val Ala Gln Gly Phe
 275 280 285
 Val His Asp Val Ala Lys Ala His Phe Gly Gly Asp Phe Ser Gly His
 290 295 300
 Gln Ala Tyr Leu Cys Gly Pro Pro Ala Met Ile Asp Ala Cys Ile Thr
 305 310 315 320
 Thr Leu Met Gln Gly Arg Leu Phe Glu Arg Asp Ile Tyr His Glu Lys
 325 330 335
 Phe Ile Ser Ala Ala Asp Ala Gln Gln Thr Arg Ser Pro Leu Phe Arg
 340 345 350

<210> 8

<211> 118

<212> PRT

<213> Burkholderia cepacia

<220>

<223> TomQ polypeptide

<400> 8

Met Asp Ala Gly Arg Val Cys Gly Thr Val Thr Ile Ala Gln Thr Asp
 5 10 15
 Glu Arg Tyr Ala Cys Val Ser Gly Glu Ser Leu Leu Ala Gly Met Ala
 20 25 30
 Lys Leu Gly Arg Arg Gly Ile Pro Val Gly Cys Leu Asn Gly Gly Cys
 35 40 45
 Gly Val Cys Lys Val Arg Val Leu Arg Gly Ala Val Arg Lys Leu Gly
 50 55 60
 Pro Ile Ser Arg Ala His Val Ser Ala Glu Glu Glu Asn Asp Gly Tyr
 65 70 75 80
 Ala Leu Ala Cys Arg Val Val Pro Asp Gly Asp Val Glu Leu Glu Val
 85 90 95
 Ala Gly Arg Leu Arg Lys Pro Phe Phe Cys Gly Met Ala Cys Ala Gly
 100 105 110
 Thr Ala Ala Ile Asn Lys
 115


<210> 9

<211> 36

<212> DNA
<213> Artificial Sequence
<223> Designed PCR primer
<400> 9
agtcgcgcat ggaggcgaca ccgatcatga atcagc 36
<210> 10
<211> 34
<212> DNA
<213> Artificial Sequence
<220>
<223> Designed PCR Primer
<400> 10
caccgacccat ggatcagcac cccaccgatc ttcc 34
<210> 11
<211> 34
<212> DNA
<213> Artificial Sequence
<223> Designed PCR primer
<400> 11
tgccgccttc catgggttct gccgcgaaca gcag 34
<210> 12
<211> 39
<212> DNA
<220>
<213> Artificial Sequence
<223> Designed PCR primer
<400> 12
agcaagccat ggccatcgag ctgaagacag tcgacatca 39
<210> 13
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<223> Designed PCR primer
<400> 13
ccgaccatca cctgctcggc cagatggaag tcgag 35

WHAT IS CLAIMED IS:

1. A DNA fragment of about 5.8 Kb containing a toluene monooxygenase gene, having 1 BamHI restriction site, 2 EcoRI restriction sites, 1 HpaI restriction site, 1 KpnI restriction site, 1 NcoI restriction site, 1 NspV restriction site, 1 SacI restriction site, 2 SmaI restriction sites, 3 SphI restriction sites, 2 XhoI restriction sites, no ClaI restriction site, no DraI restriction site, no EcoRV restriction site, no HindIII restriction site, no NdeI restriction site, no NheI restriction site, no PvuII restriction site, no ScaI restriction site, no Sse8387I restriction site, no StuI restriction site, and no XbaI restriction site, and having a restriction map of:



2. The DNA fragment according to claim 1, wherein the DNA fragment has a nucleotide sequence of SEQ ID NO: 1 in the Sequence Listing.

3. A DNA fragment having a nucleotide sequence of

SEQ ID NO: 1 with deletion, substitution, and/or addition of one or more nucleotides encoding a protein having a toluene monooxygenase activity.

5 4. A recombinant DNA comprising a vector enabling maintenance or replication in a host and a DNA fragment according to any one of claims 1 to 3.

10 5. The recombinant DNA fragment according to claim 4, wherein the vector can be maintained or replicate in a bacterium.

15 6. A DNA fragment containing a region encoding a toluene monooxygenase, the region comprising a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third sequence encoding a polypeptide TomN having an amino acid sequence of SEQ ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an amino acid sequence of SEQ ID NO: 7 of the Sequence Listing, and the first to fifth sequences are aligned so that expressed TomL - TomP polypeptides can form an active monooxygenase protein.

20

25

7. The DNA fragment according to claim 6, wherein no spacer sequence is present between the first to fifth sequences or at least one spacer sequence is present between the first to fifth sequences.

5

8. The DNA fragment according to claim 6 or 7, further comprising a sequence encoding a polypeptide TomQ having an amino acid sequence of SEQ ID NO: 8 in the Sequence Listing.

10

9. A DNA fragment containing a region encoding a toluene monooxygenase, wherein the region comprises a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third sequence encoding a polypeptide TomN having an amino acid sequence of SEQ ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an amino acid sequence of SEQ ID NO: 7, and the first to fifth sequences are aligned so that expressed TomL - TomP polypeptides can form an active monooxygenase protein;

15

20

25

wherein in at least one of the first to fifth sequences of the DNA fragment, deletion, substitution, and/or addition of one or more nucleotides are present

in the proviso that the toluene monooxygenase protein is active.

10. A DNA fragment comprising a region encoding a polypeptide TomK the polypeptide TomK having an amino acid sequence of SEQ ID NO: 2, and a property to enhance the toluene monooxygenase activity of a protein comprised of at least TomL to TomP; or a region encoding a variant TomK in which the amino acid sequence of SEQ ID NO: 2 is altered with the proviso that the property to enhance the toluene monooxygenase activity is not impaired.

11. A recombinant DNA comprising a vector, a promoter, and the DNA fragment according to any one of claims 6 to 9, and the vector and the promoter are functionally ligated to the DNA fragment to enable expression of the toluene monooxygenase encoded by the DNA fragment.

20

12. The recombinant DNA according to claim 11 wherein the promoter and the vector can function in a bacterium.


13. A recombinant DNA comprising a vector; a first promoter and the DNA fragment encoding polypeptide TomK according to claim 10 wherein the DNA

fragment for TomK polypeptide is functionally linked to the first promoter to be expressed by the first promoter; a second promoter and the DNA fragment according to any one of claims 6 to 9 wherein the DNA
5 fragment is functionally linked to the second promoter to be expressed by the second promoter.

14. The recombinant DNA according to claim 13, wherein the first and second promoters and the vector
10 can function in a bacterium.

15. A transformant obtained by introducing a recombinant DNA into a host microorganism, the recombinant DNA comprising a vector enabling
15 maintenance or replication in a host and a DNA fragment of about 5.8 Kb containing a toluene monooxygenase gene having 1 BamHI restriction site, 2 EcoRI restriction sites, 1 HpaI restriction site, 1 KpnI restriction site, 1 NcoI restriction site, 1 NspV restriction site,
20 1 SacI restriction site, 2 SmaI restriction sites, 3 SphI restriction sites, 2 XhoI restriction sites, no ClaI restriction site, no DraI restriction site, no EcoRV restriction site, no HindIII restriction site, no NdeI restriction site, no NheI restriction site, no
25 PvuII restriction site, no ScaI restriction site, no Sse8387I restriction site, no StuI restriction site, and no XbaI restriction site, and having a restriction

map of:



10 16. The transformant according to claim 15,
wherein the host microorganism is a bacterium.

15 17. A transformant obtained by introducing a
recombinant DNA into a host microorganism, where the
recombinant DNA comprises a vector enabling maintenance
or replication in a host, and a DNA fragment ligated
thereto having a nucleotide sequence of SEQ ID NO: 1 of
the Sequence Listing with deletion, substitution
and/or addition of one or more nucleotides, still
20 encoding an active toluene monooxygenase.

 18. The transformant according to claim 17,
wherein the host microorganism is a bacterium.

25 19. A transformant obtained by introducing a
recombinant DNA comprising a vector, a promoter and a
DNA fragment into a host microorganism where the DNA

fragment contains a region encoding a toluene monooxygenase, the region comprising a first sequence encoding a polypeptide TomL having an amino acid sequence of SEQ ID NO: 3, a second sequence encoding a polypeptide TomM having an amino acid sequence of SEQ ID NO: 4, a third sequence encoding a polypeptide TomN having an amino acid sequence of SEQ ID NO: 5, a fourth sequence encoding a polypeptide TomO having an amino acid sequence of SEQ ID NO: 6, and a fifth sequence encoding a polypeptide TomP having an amino acid sequence of SEQ ID NO: 7, and the first to fifth sequences are aligned so that expressed TomL - TomP polypeptides can form an active monooxygenase protein;

wherein the promoter and the DNA fragment are functionally linked enabling expression of the toluene monooxygenase protein encoded by the DNA fragment.

20. The transformant according to claim 19, wherein said host microorganism is a bacterium.

21. A method for producing a toluene monooxygenase, comprising a step of making the transformant according to any one of claims 15, 17 and 19 produce a toluene monooxygenase that is a gene product of the recombinant DNA introduced into the transformant.

22. A method for degrading at least one of a
chlorinated aliphatic hydrocarbon compound and an
aromatic compound in a medium comprising a step of
degrading at least one of a chlorinated aliphatic
5 hydrocarbon compound and an aromatic compound by using
the transformant according to any one of claims 15, 17
and 19.

23. The degradation method according to claim 22,
10 wherein the medium is an aqueous medium.

24. The degradation method according to claim 22,
wherein the medium is soil.

25. The degradation method according to claim 22,
15 wherein the medium is air.

26. The degradation method according to claim 22,
wherein the chlorinated aliphatic hydrocarbon compound
20 is either trichloroethylene (TCE) or dichloroethylene
(DCE).

27. The degradation method according to claim 22,
wherein the aromatic compound is at least one of
25 toluene, benzene, phenol, and cresol.

28. A method for cleaning a medium polluted with

at least one of a chlorinated aliphatic hydrocarbon
compound and aromatic compound comprising a step of
degrading at least one of a chlorinated aliphatic
hydrocarbon compound and an aromatic compound using the
5 transformant according to any one of claims 15, 17 and
19.

29. The cleaning method according to claim 28
wherein the medium is an aqueous medium.

10 30. The cleaning method according to claim 28
wherein the medium is soil.

31. The cleaning method according to claim 28
15 wherein the medium is air.

32. The cleaning method according to claim 28
wherein the chlorinated aliphatic hydrocarbon compound
is either trichloroethylene (TCE) or dichloroethylene
20 (DCE).

33. The cleaning method according to claim 28
wherein the aromatic compound is at least one of
toluene, benzene, phenol, and cresol.

25 34. A method for remedying an environment
polluted with a pollutant being at least either of a

chlorinated aliphatic hydrocarbon compound or an aromatic compound, comprising a step of degrading the pollutant by using the transformant according to any one of claims 15, 17 and 19.

5

35. The remediation method according to claim 34 wherein the environment is made of an aqueous medium.

36. The remediation method according to claim 35
10 wherein the polluted aqueous medium is brought into contact with a carrier holding the transformant.

37. The remediation method according to claim 36
15 wherein the contact is carried out by placing the carrier holding the transformant in a container, introducing the polluted aqueous medium from one side of the container, and discharging the remedied aqueous medium from another side.

20 38. The remediation method according to claim 34, wherein the environment is made of soil.

39. The remediation method according to claim 38
25 being carried out by introducing an aqueous medium containing the transformant into the polluted soil and supplying nutrients and/or oxygen for proliferation of the transformant in the polluted soil.

40. The remediation method according to claim 39 wherein the transformant is introduced in the soil with applying pressure through an injection well provided in the polluted soil.

5

41. The remediation method according to claim 38 wherein the polluted soil is introduced in a liquid phase containing the transformant.

10

42. The remediation method according to claim 38 wherein the polluted soil is brought into contact with a carrier holding the transformant.

15

43. The remediation method according to claim 34 wherein the environment is made of air.

20

44. The remediation method according to claim 43 wherein the polluted air is introduced into a liquid phase containing the transformant.

45. The remediation method according to claim 43 wherein the polluted air is brought into contact with a carrier holding the transformant.

25

46. The remediation method according to claim 45 wherein contact is carried out by placing the carrier holding the transformant in a container, introducing

polluted air from one side of the container, and
discharging cleaned air from another side.

47. The remediation method according to claim 34
5 wherein the chlorinated aliphatic hydrocarbon compound
is either trichloroethylene (TCE) or dichloroethylene
(DCE).

48. The remediation method according to claim 34
10 wherein the aromatic compound is at least one of
toluene, benzene, phenol, and cresol.

49. A component polypeptide having any one of
amino acid sequences of SEQ ID NOs: 2 to 8 in the
15 sequence listing, capable of being a component of a
toluene monooxygenase.

50. A toluene monooxygenase comprising at least
component polypeptides TomL to TomP having amino acid
20 sequences of SEQ ID NOs: 3 to 7 in the Sequence
Listing.

51. The toluene monooxygenase according to claim
50 further comprising a component polypeptide TomQ
25 having an amino acid sequence of SEQ ID NO: 8 in the
Sequence Listing.

52. The toluene monooxygenase according to claim
50 further comprising a component polypeptide TomQ
having an amino acid sequence of SEQ ID NO: 8 in the
Sequence Listing.

5

53. The toluene monooxygenase according to claim
52 further comprising a component polypeptide TomQ
having an amino acid sequence of SEQ ID NO: 8 in the
Sequence Listing.

10

54. A variant toluene monooxygenase comprising at
least component polypeptides TomL-TomP of amino acid
sequences of SEQ ID Nos.: 3 to 7 wherein one or more
amino acids have been deleted from, substituted to,
and/or added to the polypeptides with the proviso that
the enzyme activity is not impaired.

15

55. A recombinant DNA comprising a vector, a
promoter, a first DNA fragment being the DNA fragment
of any one of claims 6 to 9, and a second DNA fragment
being the tomK DNA fragment of claim 10, wherein the
first DNA fragment is functionally connected to the
promoter to express an active toluene monooxygenase,
and the second DNA fragment is functionally connected
to the promoter to express a property to enhance the
toluene monooxygenase activity.

20

25

ABSTRACT OF THE DISCLOSURE

A recombinant DNA is constructed by using a toluene monooxygenase gene isolated from Burkholderia cepacia strain KK01 and employed to provide the

5 transformant which can express toluene monooxygenase useful for cleaning of aqueous media such as drain and waste water containing chlorinated aliphatic hydrocarbon compounds or aromatic compounds, for

10 remediation of soil polluted with such compounds, and cleaning of air (gas phase) polluted with volatile organic chlorine compounds.

FIG. 1




FIG. 2

FIG. 2A
FIG. 2B
FIG. 2C
FIG. 2D
FIG. 2E
FIG. 2F
FIG. 2G
FIG. 2H
FIG. 2I
FIG. 2J
FIG. 2K
FIG. 2L
FIG. 2M
FIG. 2N
FIG. 2O
FIG. 2P
FIG. 2Q
FIG. 2R

FIG. 2A

GATCATTTC	TCAAATGCGC	TCGAGCGGGT	TGCTCAAATG	ATGAAAAAGG	CCACCGGACA	60
TGGGTTTCGG	CACGATCGCC	GGCGGGCGTT	TTCCGTTCTG	GTTAACCGCC	ATTGTGGGTC	120
GCGAAATTTA	ACTTCGCGTC	AGGGCTTTCC	CTGAATTATC	GAGATTTTTT	GCTGCCTGGG	180
TCGAACGTGG	CACGGATGCT	GCATTGAAGT	CCGGCATGGA	GGCGACACCG	ATC	233
ATG AAT CAG CAC CCC ACC GAT CTT TCC CCG TTC GAT CCC GGC CGC AAG						281
Met Asn Gln His Pro Thr Asp Leu Ser Pro Phe Asp Pro Gly Arg Lys						
	5		10		15	
TGC GTC CGC GTG ACC GGC ACG AAC GCG CGC GGC TTC GTC GAA TTC GAG						329
Cys Val Arg Val Thr Gly Thr Asn Ala Arg Gly Phe Val Glu Phe Glu						
	20		25		30	
CTG TCG ATC GGC GGC GCG CCG GAA CTG TGC GTC GAG CTG ACG TTG TCT						377
Leu Ser Ile Gly Gly Ala Pro Glu Leu Cys Val Glu Leu Thr Leu Ser						
	35		40		45	
CCT GCC GCC TTC GAT GCG TTC TGC CGC GAA CAG CAG GTC ACG CGG CTC						425
Pro Ala Ala Phe Asp Ala Phe Cys Arg Glu Gln Gln Val Thr Arg Leu						
	50		55		60	
GAC GTC GAA GCG AAC CCA						443
Asp Val Glu Ala Asn Pro						
65		70				

FIG. 2B

TGACCTTGAGGAGCAAGAA	462
GTG ACC ATC GAG CTG AAG ACA GTC GAC ATC AAG CCG CTC CGG CAC ACC	510
Met Thr Ile Glu Leu Lys Thr Val Asp Ile Lys Pro Leu Arg His Thr	
5 10 15	
TTT GCG CAT GTC GCG CAG AAC ATC GGC GGC GAC AAG ACG GCG ACG CGC	558
Phe Ala His Val Ala Gln Asn Ile Gly Gly Asp Lys Thr Ala Thr Arg	
20 25 30	
TAC CAG GAA GGC ATG ATG GGC GCG CAG CCC CAG GAG AAC TTC CAT TAC	606
Tyr Gln Glu Gly Met Met Gly Ala Gln Pro Gln Glu Asn Phe His Tyr	
35 40 45	
CGG CCG ACC TGG GAC CCG GAC TAC GAG ATC TTC GAT CCG TCG CGC TCG	654
Arg Pro Thr Trp Asp Pro Asp Tyr Glu Ile Phe Asp Pro Ser Arg Ser	
50 55 60	
GCG ATC CCG ATG GCG AAC TGG TAC GCG TTG AAG GAT CCG CGC CAG TTC	702
Ala Ile Arg Met Ala Asn Trp Tyr Ala Leu Lys Asp Pro Arg Gln Phe	
65 70 75 80	
TAC TAC GCG TCG TGG GCG ACC ACG CGG GCG CGC CAG CAG GAT GCG ATG	750
Tyr Tyr Ala Ser Trp Ala Thr Thr Arg Ala Arg Gln Gln Asp Ala Met	
85 90 95	

FIG. 2C

GAG TCG AAC TTC GAG TTC GTC GAA TCG CGC CGG ATG ATC GGC CTG ATG	798
Glu Ser Asn Phe Glu Phe Val Glu Ser Arg Arg Met Ile Gly Leu Met	
100 105 110	
CGC GAC GAC GTG GCC GCG CGG GCG CTC GAC GTG CTG GTG CCG CTG CGC	846
Arg Asp Asp Val Ala Ala Arg Ala Leu Asp Val Leu Val Pro Leu Arg	
115 120 125	
CAC GCC GCG TGG GGC GCG AAC ATG AAC AAC GCG CAG ATC TGC GCG CTC	894
His Ala Ala Trp Gly Ala Asn Met Asn Asn Ala Gln Ile Cys Ala Leu	
130 135 140	
GGC TAC GGC ACG GTG TTC ACC GCG CCC GCG ATG TTC CAT GCG ATG GAC	942
Gly Tyr Gly Thr Val Phe Thr Ala Pro Ala Met Phe His Ala Met Asp	
145 150 155 160	
AAC CTC GGC GTC GCG CAA TAC CTC ACG CGT CTC GCG CTC GCG ATG GCC	990
Asn Leu Gly Val Ala Gln Tyr Leu Thr Arg Leu Ala Leu Ala Met Ala	
165 170 175	
GAG CCC GAC GTG CTG GAG GCG GCC AAG GCG ACC TGG ACC CGC GAC GCC	1038
Glu Pro Asp Val Leu Glu Ala Ala Lys Ala Thr Trp Thr Arg Asp Ala	
180 185 190	

FIG. 2D

GCC TGG CAG CCG CTG CGC CGC TAC GTC GAG GAC ACG CTG GTC GTC GCC 1086

Ala Trp Gln Pro Leu Arg Arg Tyr Val Glu Asp Thr Leu Val Val Ala

195

200

205

GAT CCG GTC GAG CTG TTC ATC GCG CAG AAC CTC GCG CTC GAC GGC CTG 1134

Asp Pro Val Glu Leu Phe Ile Ala Gln Asn Leu Ala Leu Asp Gly Leu

210

215

220

CTG TAT CCG CTC GTC TAC GAC CGC TTC GTC GAC GAA CGG ATC GCG CTC 1182

Leu Tyr Pro Leu Val Tyr Asp Arg Phe Val Asp Glu Arg Ile Ala Leu

225

230

235

240

GAA GGC GGC TCG GCA GTC GCG ATG CTG ACC GCG TTC ATG CCC GAA TGG 1230

Glu Gly Gly Ser Ala Val Ala Met Leu Thr Ala Phe Met Pro Glu Trp

245

250

255

CAC ACC GAG TCG AAC CGC TGG ATC GAC GCG GTC GTG AAG ACG ATG GCC 1278

His Thr Glu Ser Asn Arg Trp Ile Asp Ala Val Val Lys Thr Met Ala

260

265

270

GCC GAA TCC GAC GAC AAC CGC GCG CTG CTC GCC CGC TGG ACA CGC GAC 1326

Ala Glu Ser Asp Asp Asn Arg Ala Leu Leu Ala Arg Trp Thr Arg Asp

275

280

285

FIG. 2E

TGG TCC GCG CGC GCC GAG GCG GCA CTG GCA CCG GTG GCG GCA CGC GCG 1374

Trp Ser Ala Arg Ala Glu Ala Ala Leu Ala Pro Val Ala Ala Arg Ala

290

295

300

CTG CAG GAT GCC GGG CGC GCG GCG CTC GAC GAA GTG CGC GAG CAG TTC 1422

Leu Gln Asp Ala Gly Arg Ala Ala Leu Asp Glu Val Arg Glu Gln Phe

305

310

315

320

CAC GCA CGC GCG GCC AGG CTC GGC ATC GCG CTC

1455

His Ala Arg Ala Ala Arg Leu Gly Ile Ala Leu

325

330

TGACGACGGG AATCCTCCCT TAACCCAAGG AATGCCAGC

1494

ATG TCC AAC GTA TTC ATC GCC TTT CAG GCC AAT GAG GAC TCC AGA CCG 1542

Met Ser Asn Val Phe Ile Ala Phe Gln Ala Asn Glu Asp Ser Arg Pro

5

10

15

ATC GTG GAT GCG ATC GTC GCC GAC AAC CCG CGC GCG GTG GTG GTC GAG 1590

Ile Val Asp Ala Ile Val Ala Asp Asn Pro Arg Ala Val Val Val Glu

20

25

30

TCG CCC GGC ATG GTC AAG ATC GAC GCG CCG GAC CGG CTG ACG ATC CGC 1638

Ser Pro Gly Met Val Lys Ile Asp Ala Pro Asp Arg Leu Thr Ile Arg

35

40

45

FIG. 2F

CGC GAA ACG ATC GAG GAA CTG ACC GGC ACG CGC TTC GAC CTG CAG CAG 1686

Arg Glu Thr Ile Glu Glu Leu Thr Gly Thr Arg Phe Asp Leu Gln Gln

50

55

60

CTC CAG GTC AAC CTG ATC ACG CTG TCA GGC CAC ATC GAC GAG GAC GAC 1734

Leu Gln Val Asn Leu Ile Thr Leu Ser Gly His Ile Asp Glu Asp Asp

65

70

75

80

GAC GAG TTC ACG CTG AGC TGG TCG CAC 1761

Asp Glu Phe Thr Leu Ser Trp Ser His

85

TGAACGCCGC GCCACGCGCA CCGACAACAC CGGAGACACG A 1802

ATG GAC ACG CCA ACG CTC AAG AAA AAA CTC GGC CTG AAG GAC CGC TAC 1850

Met Asp Thr Pro Thr Leu Lys Lys Lys Leu Gly Leu Lys Asp Arg Tyr

5

10

15

GCG GCA ATG ACG CGC GGC CTC GGC TGG GAG ACG ACC TAC CAG CCG ATG 1898

Ala Ala Met Thr Arg Gly Leu Gly Trp Glu Thr Thr Tyr Gln Pro Met

20

25

30

GAC AAG GTC TTC CCG TAC GAC CGC TAC GAG GGC ATC AAG ATC CAC GAC 1946

Asp Lys Val Phe Pro Tyr Asp Arg Tyr Glu Gly Ile Lys Ile His Asp

35

40

45

FIG. 2G

TGG GAC AAG TGG GTC GAC CCG TTC CGC CTG ACG ATG GAT GCG TAC TGG 1994

Trp Asp Lys Trp Val Asp Pro Phe Arg Leu Thr Met Asp Ala Tyr Trp

50

55

60

AAA TAC CAG GGC GAG AAG GAA AAG AAG CTG TAC GCG GTG ATC GAC GCG 2042

Lys Tyr Gln Gly Glu Lys Glu Lys Lys Leu Tyr Ala Val Ile Asp Ala

65

70

75

80

TTC ACG CAG AAC AAC GCG TTC CTC GGC GTG AGC GAC GCC CGC TAC ATC 2090

Phe Thr Gln Asn Asn Ala Phe Leu Gly Val Ser Asp Ala Arg Tyr Ile

85

90

95

AAC GCG CTG AAG CTG TTC CTC CAG GGC GTG ACG CCG CTC GAA TAC CTC 2138

Asn Ala Leu Lys Leu Phe Leu Gln Gly Val Thr Pro Leu Glu Tyr Leu

100

105

110

GCG CAC CGC GGC TTC GCG CAT GTC GGC CGG CAC TTC ACC GGC GAG GGC 2186

Ala His Arg Gly Phe Ala His Val Gly Arg His Phe Thr Gly Glu Gly

115

120

125

GCG CGC ATC GCG TGC CAG ATG CAG TCG ATC GAC GAG CTG CGG CAC TAC 2234

Ala Arg Ile Ala Cys Gln Met Gln Ser Ile Asp Glu Leu Arg His Tyr

130

135

140

FIG. 2H

CAG ACC GAA ACG CAT GCG ATG TCG ACG TAC AAC AAG TTC TTC AAC GGG 2282

Gln Thr Glu Thr His Ala Met Ser Thr Tyr Asn Lys Phe Phe Asn Gly

145 150 155 160

TTC CAT CAC TCG AAC CAG TGG TTC GAC CGC GTG TGG TAC CTG TCG GTG 2330

Phe His His Ser Asn Gln Trp Phe Asp Arg Val Trp Tyr Leu Ser Val

165 170 175

CCG AAG TCG TTC TTC GAG GAC GCG TAT TCG TCG GGG CCG TTC GAG TTC 2378

Pro Lys Ser Phe Phe Glu Asp Ala Tyr Ser Ser Gly Pro Phe Glu Phe

180 185 190

CTG ACC GCG GTC AGC TTC TCG TTC GAA TAC GTG CTG ACG AAC CTG CTG 2426

Leu Thr Ala Val Ser Phe Ser Phe Glu Tyr Val Leu Thr Asn Leu Leu

195 200 205

TTC GTG CCG TTC ATG TCG GGC GCC GCC TAC AAC GGT GAC ATG TCG ACC 2474

Phe Val Pro Phe Met Ser Gly Ala Ala Tyr Asn Gly Asp Met Ser Thr

210 215 220

GTC ACG TTC GGC TTC TCC GCG CAG TCG GAC GAA TCG CGT CAC ATG ACG 2522

Val Thr Phe Gly Phe Ser Ala Gln Ser Asp Glu Ser Arg His Met Thr

225 230 235 240

FIG. 21

CTC GGC ATC GAA TGC ATC AAG TTC CTG CTC GAA CAG GAC CCG GAC AAC 2570

Leu Gly Ile Glu Cys Ile Lys Phe Leu Leu Glu Gln Asp Pro Asp Asn

245

250

255

GTG CCG ATC GTG CAG CGC TGG ATC GAC AAG TGG TTC TGG CGC GGC TAC 2618

Val Pro Ile Val Gln Arg Trp Ile Asp Lys Trp Phe Trp Arg Gly Tyr

260

265

270

CGG CTG CTG ACG CTG GTC GCG ATG ATG ATG GAC TAC ATG CAG CCC AAG 2666

Arg Leu Leu Thr Leu Val Ala Met Met Met Asp Tyr Met Gln Pro Lys

275

280

285

CGC GTG ATG AGC TGG CGC GAG TCG TGG GAG ATG TAC GCC GAG CAG AAC 2714

Arg Val Met Ser Trp Arg Glu Ser Trp Glu Met Tyr Ala Glu Gln Asn

290

295

300

GGC GGC GCG CTG TTC AAG GAT CTC GCG CGC TAC GGC ATT CGC GAG CCG 2762

Gly Gly Ala Leu Phe Lys Asp Leu Ala Arg Tyr Gly Ile Arg Glu Pro

305

310

315

320

AAG GGC TGG CAG GAC GCC TGC GAA GGC AAG GAT CAC ATC AGC CAC CAG 2810

Lys Gly Trp Gln Asp Ala Cys Glu Gly Lys Asp His Ile Ser His Gln

325

330

335

FIG. 2J

GCG TGG TCG ACG TTC TAC GGC TTC AAC GCG GCC TCG GCG TTC CAC ACC 2858

Ala Trp Ser Thr Phe Tyr Gly Phe Asn Ala Ala Ser Ala Phe His Thr

340

345

350

TGG GTG CCG ACC GAA GAC GAA ATG GGC TGG CTG TCG GCG AAG TAT CCC 2906

Trp Val Pro Thr Glu Asp Glu Met Gly Trp Leu Ser Ala Lys Tyr Pro

355

360

365

GAC TCG TTC GAC CGC TAC TAC CGC CCG CGC TTC GAT CAC TGG GGC GAG 2954

Asp Ser Phe Asp Arg Tyr Tyr Arg Pro Arg Phe Asp His Trp Gly Glu

370

375

380

CAG GCC AGG GCC GGC AAC CGC TTC TAC ATG AAG ACG CTG CCG ATG CTG 3002

Gln Ala Arg Ala Gly Asn Arg Phe Tyr Met Lys Thr Leu Pro Met Leu

385

390

395

400

TGC CAG ACG TGC CAG ATC CCG ATG CTG TTC ACC GAG CCG GGC AAC CCG 3050

Cys Gln Thr Cys Gln Ile Pro Met Leu Phe Thr Glu Pro Gly Asn Pro

405

410

415

ACG AAG ATC GGC GCG CGC GAA TCG AAC TAC CTC GGC AAC AAG TTC CAC 3098

Thr Lys Ile Gly Ala Arg Glu Ser Asn Tyr Leu Gly Asn Lys Phe His

420

425

430

FIG. 2K

TTC TGC AGC GAC CAC TGC AAG GAC ATC TTC GAT CAC GAG CCG CAG AAA 3146

Phe Cys Ser Asp His Cys Lys Asp Ile Phe Asp His Glu Pro Gln Lys

435

440

445

TAC GTG CAG GCG TGG CTG CCG GTG CAC CAG ATC CAT CAG GGC AAC TGC 3194

Tyr Val Gln Ala Trp Leu Pro Val His Gln Ile His Gln Gly Asn Cys

450

455

460

TTC CCG CCC GAT GCG GAC CCG GGC GCG GAG GGC TTC GAT CCG CTC GCC 3242

Phe Pro Pro Asp Ala Asp Pro Gly Ala Glu Gly Phe Asp Pro Leu Ala

465

470

475

480

GCG GTG CTC GAC TAC TAC GCG GTG ACG ATG GGC CGC GAC AAC CTC GAT 3290

Ala Val Leu Asp Tyr Tyr Ala Val Thr Met Gly Arg Asp Asn Leu Asp

485

490

495

TTC GAC GGC TCG GAA GAC CAG AAG AAC TTC GCG GCG TGG CGC GGC CAG 3338

Phe Asp Gly Ser Glu Asp Gln Lys Asn Phe Ala Ala Trp Arg Gly Gln

500

505

510

GCC ACG CGC AAC

3350

Ala Thr Arg Asn

515

FIG. 2L

TGACCCGCAA CGACAAGCAA TCTTGACGAG GGCCCGCGAA GCGCCGATGC GCGAACGCGG 3410
 GCCGACAGGA GACAAAC 3427
 ATG GCC GTC ATC GCG CTC AAA CCC TAC GAC TTC CCG GTG AAG GAT GCC 3475
 Met Ala Val Ile Ala Leu Lys Pro Tyr Asp Phe Pro Val Lys Asp Ala
 5 10 15
 GTC GAG AAG TTT CCG GCG CCG CTG CTC TAC GTG TGC TGG GAA AAC CAT 3523
 Val Glu Lys Phe Pro Ala Pro Leu Leu Tyr Val Cys Trp Glu Asn His
 20 25 30
 CTG ATG TTC CCG GCG CCG TTC TGC CTG CCG CTG CCG CCC GAC ATG CCG 3571
 Leu Met Phe Pro Ala Pro Phe Cys Leu Pro Leu Pro Pro Asp Met Pro
 35 40 45
 TTC GGC GCG CTG GCC GGC GAC GTG CTG CCG CCC GTC TAC GGC TAT CAC 3619
 Phe Gly Ala Leu Ala Gly Asp Val Leu Pro Pro Val Tyr Gly Tyr His
 50 55 60
 CCC GAC TTC GCG AAG ATC GAC TGG GAT CGC GTC GAG TGG TTC CCG TCG 3667
 Pro Asp Phe Ala Lys Ile Asp Trp Asp Arg Val Glu Trp Phe Arg Ser
 65 70 75 80
 GGC GAG CCG TGG GCG CCG GAC CCG GCG AAG AGC CTG GCC GGC AAC GGC 3715
 Gly Glu Pro Trp Ala Pro Asp Pro Ala Lys Ser Leu Ala Gly Asn Gly
 85 90 95

FIG. 2M

CTC GGG CAC AAG GAC CTG ATC AGC TTC CGC ACG CCC GGC CTC GAC GGC 3763

Leu Gly His Lys Asp Leu Ile Ser Phe Arg Thr Pro Gly Leu Asp Gly

100

105

110

CTC GGC GGC GCG AGC TTC

3781

Leu Gly Gly Ala Ser Phe

115

TGACCGCCAC GCGGACGAGC GAACCATC

3809

ATG AGC CAC CAA CTT ACC ATC GAG CCG CTG GGC GTC ACG ATC GAG GTC 3857

Met Ser His Gln Leu Thr Ile Glu Pro Leu Gly Val Thr Ile Glu Val

5

10

15

GAG GAA GGA CAG ACG ATG CTC GAT GCC GCG CTG CGC CAG GGC ATC TAC 3905

Glu Glu Gly Gln Thr Met Leu Asp Ala Ala Leu Arg Gln Gly Ile Tyr

20

25

30

ATT CCG CAC GCG TGC TGT CAC GGG CTG TGC GGC ACC TGC AAG GTC GCC 3953

Ile Pro His Ala Cys Cys His Gly Leu Cys Gly Thr Cys Lys Val Ala

35

40

45

GTG CTC GAC GGC GAG ACC GAT CCC GGC GAT GCG AAC CCG TTC GCG CTG 4001

Val Leu Asp Gly Glu Thr Asp Pro Gly Asp Ala Asn Pro Phe Ala Leu

50

55

60

FIG. 2N

ATG GAT TTC GAG CGC GAG GAA GGC AAG GCG CTC GCG TGC TGC GCG ACG 4049
 Met Asp Phe Glu Arg Glu Glu Gly Lys Ala Leu Ala Cys Cys Ala Thr
 65 70 75 80
 CTG CAG GCC GAC ACC GTG ATC GAG GCC GAC GTC GAC GAG GAG CCG GAT 4097
 Leu Gln Ala Asp Thr Val Ile Glu Ala Asp Val Asp Glu Glu Pro Asp
 85 90 95
 GCG GAA ATC ATC CCG GTC AGG GAC TTC GCG GCC GAC GTC ACG CGC ATC 4145
 Ala Glu Ile Ile Pro Val Arg Asp Phe Ala Ala Asp Val Thr Arg Ile
 100 105 110
 GAA CAG CTC ACG CCG ACC ATC AAG TCG ATC CGC CTG AAG CTG TCG CAG 4193
 Glu Gln Leu Thr Pro Thr Ile Lys Ser Ile Arg Leu Lys Leu Ser Gln
 115 120 125
 CCG ATC CGC TTC CAG GCG GGC CAG TAC GTG CAG CTC GAG ATT CCC GGC 4241
 Pro Ile Arg Phe Gln Ala Gly Gln Tyr Val Gln Leu Glu Ile Pro Gly
 130 135 140
 CTC GGG CAG AGC CGC GCG TTC TCG ATC GCG AAC GCG CCG GCC GAC GTC 4289
 Leu Gly Gln Ser Arg Ala Phe Ser Ile Ala Asn Ala Pro Ala Asp Val
 145 150 155 160

FIG. 20

CGC GCC ACC GGC GAG ATC GAA CTG AAC GTG CGG CAG GTG CCG GGC GGG 4337

Ala Ala Thr Gly Glu Ile Glu Leu Asn Val Arg Gln Val Pro Gly Gly

165

170

175

CTC GGC ACG GGC TAC CTG CAC GAG CAA CTG GCG ACG GGC GAG CGC GTG 4385

Leu Gly Thr Gly Tyr Leu His Glu Gln Leu Ala Thr Gly Glu Arg Val

180

185

190

CGC CTG TCG GGC CCG TAC GGC CGC TTC TTC GTG CGT CGC TCG GCC GCG 4433

Arg Leu Ser Gly Pro Tyr Gly Arg Phe Phe Val Arg Arg Ser Ala Ala

195

200

205

CGG CCG ATG ATC TTC ATG GCC GGC GGG TCG GGG CTG TCG AGC CCG CGC 4481

Arg Pro Met Ile Phe Met Ala Gly Gly Ser Gly Leu Ser Ser Pro Arg

210

215

220

TCG ATG ATC GCG GAC CTG CTC GCA AGC GGC GTC ACC GCG CCG ATC ACG 4529

Ser Met Ile Ala Asp Leu Leu Ala Ser Gly Val Thr Ala Pro Ile Thr

225

230

235

240

CTG GTC TAC GGT CAG CGC AGC GCG CAG GAG CTC TAC TAC CAC GAC GAA 4577

Leu Val Tyr Gly Gln Arg Ser Ala Gln Glu Leu Tyr Tyr His Asp Glu

245

250

255

TTC CGC GCG CTG GCC GAA CGC CAT CCG AAC TTC ACG TAC GTG CCG GCG 4625

FIG. 2P

Phe Arg Ala Leu Ala Glu Arg His Pro Asn Phe Thr Tyr Val Pro Ala

260

265

270

CTG TCC GAA GGC GCA CCG CAC GCG GGC GGC GAC GTC GCG CAA GGG TTC 4673

Leu Ser Glu Gly Ala Pro His Ala Gly Gly Asp Val Ala Gln Gly Phe

275

280

285

GTG CAC GAC GTC GCG AAG GCA CAT TTC GGC GGC GAC TTC TCC GGG CAC 4721

Val His Asp Val Ala Lys Ala His Phe Gly Gly Asp Phe Ser Gly His

290

295

300

CAG GCG TAC CTG TGC GGG CCG CCC GCG ATG ATC GAC GCG TGC ATC ACG 4769

Gln Ala Tyr Leu Cys Gly Pro Pro Ala Met Ile Asp Ala Cys Ile Thr

305

310

315

320

ACG CTG ATG CAG GGG CGC CTG TTC GAG CGC GAC ATC TAT CAC GAG AAG 4817

Thr Leu Met Gln Gly Arg Leu Phe Glu Arg Asp Ile Tyr His Glu Lys

325

330

335

TTC ATC TCG GCG GCC GAC GCG CAA CAG ACG CGC AGC CCG CTG TTC CGG 4865

Phe Ile Ser Ala Ala Asp Ala Gln Gln Thr Arg Ser Pro Leu Phe Arg

340

345

350

CGG GTG

4871

Arg Val

TGAC

4875

FIG. 2Q

ATG GAC GCG GGC CGC GTA TGC GGG ACG GTC ACG ATC GCG CAG ACC GAC 4923

Met Asp Ala Gly Arg Val Cys Gly Thr Val Thr Ile Ala Gln Thr Asp

5

10

15

GAG CGC TAT GCG TGC GTG TCC GGC GAG TCG CTG CTG GCC GGC ATG GCG 4971

Glu Arg Tyr Ala Cys Val Ser Gly Glu Ser Leu Leu Ala Gly Met Ala

20

25

30

AAA CTC GGC CGG CGC GGC ATT CCG GTC GGC TGC CTG AAC GGC GGC TGC 5019

Lys Leu Gly Arg Arg Gly Ile Pro Val Gly Cys Leu Asn Gly Gly Cys

35

40

45

GGC GTG TGC AAG GTG CGC GTG CTG CGC GGT GCG GTG CGC AAG CTC GGC 5067

Gly Val Cys Lys Val Arg Val Leu Arg Gly Ala Val Arg Lys Leu Gly

50

55

60

CCG ATC AGC CGT GCC CAT GTG AGC GCG GAA GAA GAG AAC GAC GGC TAC 5115

Pro Ile Ser Arg Ala His Val Ser Ala Glu Glu Glu Asn Asp Gly Tyr

65

70

75

80

GCG CTT GCG TGC CGC GTC GTG CCG GAC GGC GAC GTC GAA CTC GAA GTG 5163

Ala Leu Ala Cys Arg Val Val Pro Asp Gly Asp Val Glu Leu Glu Val

85

90

95

FIG. 2R

GCC GGC CGG CTC AGG AAG CCG TTC TTC TGC GGC ATG GCA TGT GCC GGC 5211

Ala Gly Arg Leu Arg Lys Pro Phe Phe Cys Gly Met Ala Cys Ala Gly

100

105

110

ACG GCG GCG ATC AAC AAG

5229

Thr Ala Ala Ile Asn Lys

115

TAACCAGGAG GAGACTCACC ATGGGTGTGA TCGTATTGG TCATGTCAGT CTGAAGGTGA 5289

TGGACATGGA AGCGGCGCTG CGTCATTACG TACGCGTGCT CGGCATGCAG GAAACGATGC 5349

GCGACGCGGC GGGCAACGTC TACCTGAAAT GCTGGGACGA ATGGGACAAG TATTCGCTGA 5409

TCCTGTGCGC GTCCGATCAG GCGGGGCTCA AGCATGCCGC CTACAAGGTC GAGCAGGACG 5469

CCGATCTGGA TGCCTGCAG CAGCGCATCG AAGCGTACGG GATCGCGACC GAGATGCTGC 5529

CCGAAGGCGC GCTGCCGGCG GTCGGCCGCC AACTGCGGTT CCTGCTGCCG AGCGGCCATG 5589

AACTGCGGCT GTTCGGAAG AAGGCGCTGG TGGGCACCGC GGTCGGCTCG CTGAACCCCG 5649

ATCCGTGGCC CGACGACATT CCGGGCTCGG CCGTGCACTG GCTCGACCAC TGCCTGCTGA 5709

TGTGCGAACT GAACCCGGAG GCCGGCGTGA ACCGCGTCGA GGAGAACACG CGCTTCATGG 5769

CCGAGTGTCT CGACTTCCAT CTGGCCGAGC AGGTGATGGT CGGCCCGGGC AACACGATC 5828

FIG. 3

Met	Glu	Ala	Thr	Pro	Ile	Met	Asn	Gln	His	Pro	Thr	Asp	Leu	Ser	Pro
				5					10					15	
Phe	Asp	Pro	Gly	Arg	Lys	Cys	Val	Arg	Val	Thr	Gly	Thr	Asn	Ala	Arg
				20					25					30	
Gly	Phe	Val	Glu	Phe	Glu	Leu	Ser	Ile	Gly	Gly	Ala	Pro	Glu	Leu	Cys
				35					40					45	
Val	Glu	Leu	Thr	Leu	Ser	Pro	Ala	Ala	Phe	Asp	Ala	Phe	Cys	Arg	Glu
				50				55				60			
Gln	Gln	Val	Thr	Arg	Leu	Asp	Val	Glu	Ala	Asn	Pro				
				65			70				75				

FIG. 4

FIG. 4A
FIG. 4B
FIG. 4C

FIG. 4A

Met Arg Ser Ala Ala Asn Ser Arg Ser Arg Gly Ser Thr Ser Lys Arg

5

10

15

Thr His Asp Leu Glu Glu Gln Glu Val Thr Ile Glu Leu Lys Thr Val

20

25

30

Asp Ile Lys Pro Leu Arg His Thr Phe Ala His Val Ala Gln Asn Ile

35

40

45

Gly Gly Asp Lys Thr Ala Thr Arg Tyr Gln Glu Gly Met Met Gly Ala

50

55

60

Gln Pro Gln Glu Asn Phe His Tyr Arg Pro Thr Trp Asp Pro Asp Tyr

65

70

75

80

Glu Ile Phe Asp Pro Ser Arg Ser Ala Ile Arg Met Ala Asn Trp Tyr

85

90

95

Ala Leu Lys Asp Pro Arg Gln Phe Tyr Tyr Ala Ser Trp Ala Thr Thr

100

105

110

Arg Ala Arg Gln Gln Asp Ala Met Glu Ser Asn Phe Glu Phe Val Glu

115

120

125

FIG. 4B

Ser Arg Arg Met Ile Gly Leu Met Arg Asp Asp Val Ala Ala Arg Ala
 130 135 140
 Leu Asp Val Leu Val Pro Leu Arg His Ala Ala Trp Gly Ala Asn Met
 145 150 155 160
 Asn Asn Ala Gln Ile Cys Ala Leu Gly Tyr Gly Thr Val Phe Thr Ala
 165 170 175
 Pro Ala Met Phe His Ala Met Asp Asn Leu Gly Val Ala Gln Tyr Leu
 180 185 190
 Thr Arg Leu Ala Leu Ala Met Ala Glu Pro Asp Val Leu Glu Ala Ala
 195 200 205
 Lys Ala Thr Trp Thr Arg Asp Ala Ala Trp Gln Pro Leu Arg Arg Tyr
 210 215 220
 Val Glu Asp Thr Leu Val Val Ala Asp Pro Val Glu Leu Phe Ile Ala
 225 230 235 240

FIG. 4C

Gln Asn Leu Ala Leu Asp Gly Leu Leu Tyr Pro Leu Val Tyr Asp Arg

245

250

255

Phe Val Asp Glu Arg Ile Ala Leu Glu Gly Gly Ser Ala Val Ala Met

260

265

270

Leu Thr Ala Phe Met Pro Glu Trp His Thr Glu Ser Asn Arg Trp Ile

275

280

285

Asp Ala Val Val Lys Thr Met Ala Ala Glu Ser Asp Asp Asn Arg Ala

290

295

300

Leu Leu Ala Arg Trp Thr Arg Asp Trp Ser Ala Arg Ala Glu Ala Ala

305

310

315

320

Leu Ala Pro Val Ala Ala Arg Ala Leu Gln Asp Ala Gly Arg Ala Ala

325

330

335

Leu Asp Glu Val Arg Glu Gln Phe His Ala Arg Ala Ala Arg Leu Gly

340

345

350

Ile Ala Leu

355

FIG. 5

Met Ser Asn Val Phe Ile Ala Phe Gln Ala Asn Glu Asp Ser Arg Pro

15

Ile Val Asp Ala Ile Val Ala Asp Asn Pro Arg Ala Val Val Val Glu

30

Ser Pro Gly Met Val Lys Ile Asp Ala Pro Asp Arg Leu Thr Ile Arg

45

Arg Glu Thr Ile Glu Glu Leu Thr Gly Thr Arg Phe Asp Leu Gln Gln

60

Leu Gln Val Asn Leu Ile Thr Leu Ser Gly His Ile Asp Glu Asp Asp

80

Asp Glu Phe Thr Leu Ser Trp Ser His

85

FIG. 6

FIG. 6A
FIG. 6B
FIG. 6C
FIG. 6D

FIG. 6A

Met Asp Thr Pro Thr Leu Lys Lys Lys Leu Gly Leu Lys Asp Arg Tyr

5

10

15

Ala Ala Met Thr Arg Gly Leu Gly Trp Glu Thr Thr Tyr Gln Pro Met

20

25

30

Asp Lys Val Phe Pro Tyr Asp Arg Tyr Glu Gly Ile Lys Ile His Asp

35

40

45

Trp Asp Lys Trp Val Asp Pro Phe Arg Leu Thr Met Asp Ala Tyr Trp

50

55

60

Lys Tyr Gln Gly Glu Lys Glu Lys Lys Leu Tyr Ala Val Ile Asp Ala

65

70

75

80

Phe Thr Gln Asn Asn Ala Phe Leu Gly Val Ser Asp Ala Arg Tyr Ile

85

90

95

Asn Ala Leu Lys Leu Phe Leu Gln Gly Val Thr Pro Leu Glu Tyr Leu

100

105

110

Ala His Arg Gly Phe Ala His Val Gly Arg His Phe Thr Gly Glu Gly

115

120

125

FIG. 6C

Arg Leu Leu Thr Leu Val Ala Met Met Met Asp Tyr Met Gln Pro Lys

275

280

285

Arg Val Met Ser Trp Arg Glu Ser Trp Glu Met Tyr Ala Glu Gln Asn

290

295

300

Gly Gly Ala Leu Phe Lys Asp Leu Ala Arg Tyr Gly Ile Arg Glu Pro

305

310

315

320

Lys Gly Trp Gln Asp Ala Cys Glu Gly Lys Asp His Ile Ser His Gln

325

330

335

Ala Trp Ser Thr Phe Tyr Gly Phe Asn Ala Ala Ser Ala Phe His Thr

340

345

350

Trp Val Pro Thr Glu Asp Glu Met Gly Trp Leu Ser Ala Lys Tyr Pro

355

360

365

Asp Ser Phe Asp Arg Tyr Tyr Arg Pro Arg Phe Asp His Trp Gly Glu

370

375

380

Gln Ala Arg Ala Gly Asn Arg Phe Tyr Met Lys Thr Leu Pro Met Leu

385

390

395

400

Cys Gln Thr Cys Gln Ile Pro Met Leu Phe Thr Glu Pro Gly Asn Pro

FIG. 6D

405 410 415
 Thr Lys Ile Gly Ala Arg Glu Ser Asn Tyr Leu Gly Asn Lys Phe His
 420 425 430
 Phe Cys Ser Asp His Cys Lys Asp Ile Phe Asp His Glu Pro Gln Lys
 435 440 445
 Tyr Val Gln Ala Trp Leu Pro Val His Gln Ile His Gln Gly Asn Cys
 450 455 460
 Phe Pro Pro Asp Ala Asp Pro Gly Ala Glu Gly Phe Asp Pro Leu Ala
 465 470 475 480
 Ala Val Leu Asp Tyr Tyr Ala Val Thr Met Gly Arg Asp Asn Leu Asp
 485 490 495
 Phe Asp Gly Ser Glu Asp Gln Lys Asn Phe Ala Ala Trp Arg Gly Gln
 500 505 510
 Ala Thr Arg Asn
 515

FIG. 7

Met Ala Val Ile Ala Leu Lys Pro Tyr Asp Phe Pro Val Lys Asp Ala

5

10

15

Val Glu Lys Phe Pro Ala Pro Leu Leu Tyr Val Cys Trp Glu Asn His

20

25

30

Leu Met Phe Pro Ala Pro Phe Cys Leu Pro Leu Pro Pro Asp Met Pro

35

40

45

Phe Gly Ala Leu Ala Gly Asp Val Leu Pro Pro Val Tyr Gly Tyr His

50

55

60

Pro Asp Phe Ala Lys Ile Asp Trp Asp Arg Val Glu Trp Phe Arg Ser

65

70

75

80

Gly Glu Pro Trp Ala Pro Asp Pro Ala Lys Ser Leu Ala Gly Asn Gly

85

90

95

Leu Gly His Lys Asp Leu Ile Ser Phe Arg Thr Pro Gly Leu Asp Gly

100

105

110

Leu Gly Gly Ala Ser Phe

115

FIG. 8

FIG. 8A
FIG. 8B
FIG. 8C

FIG. 8A

Met Ser His Gln Leu Thr Ile Glu Pro Leu Gly Val Thr Ile Glu Val

5

10

15

Glu Glu Gly Gln Thr Met Leu Asp Ala Ala Leu Arg Gln Gly Ile Tyr

20

25

30

Ile Pro His Ala Cys Cys His Gly Leu Cys Gly Thr Cys Lys Val Ala

35

40

45

Val Leu Asp Gly Glu Thr Asp Pro Gly Asp Ala Asn Pro Phe Ala Leu

50

55

60

Met Asp Phe Glu Arg Glu Glu Gly Lys Ala Leu Ala Cys Cys Ala Thr

65

70

75

80

Leu Gln Ala Asp Thr Val Ile Glu Ala Asp Val Asp Glu Glu Pro Asp

85

90

95

Ala Glu Ile Ile Pro Val Arg Asp Phe Ala Ala Asp Val Thr Arg Ile

100

105

110

FIG. 8B

Glu Gln Leu Thr Pro Thr Ile Lys Ser Ile Arg Leu Lys Leu Ser Gln
 115 120 125
 Pro Ile Arg Phe Gln Ala Gly Gln Tyr Val Gln Leu Glu Ile Pro Gly
 130 135 140
 Leu Gly Gln Ser Arg Ala Phe Ser Ile Ala Asn Ala Pro Ala Asp Val
 145 150 155 160
 Ala Ala Thr Gly Glu Ile Glu Leu Asn Val Arg Gln Val Pro Gly Gly
 165 170 175
 Leu Gly Thr Gly Tyr Leu His Glu Gln Leu Ala Thr Gly Glu Arg Val
 180 185 190
 Arg Leu Ser Gly Pro Tyr Gly Arg Phe Phe Val Arg Arg Ser Ala Ala
 195 200 205
 Arg Pro Met Ile Phe Met Ala Gly Gly Ser Gly Leu Ser Ser Pro Arg
 210 215 220
 Ser Met Ile Ala Asp Leu Leu Ala Ser Gly Val Thr Ala Pro Ile Thr
 225 230 235 240
 Leu Val Tyr Gly Gln Arg Ser Ala Gln Glu Leu Tyr Tyr His Asp Glu
 245 250 255

FIG. 8C

Phe Arg Ala Leu Ala Glu Arg His Pro Asn Phe Thr Tyr Val Pro Ala

260

265

270

Leu Ser Glu Gly Ala Pro His Ala Gly Gly Asp Val Ala Gln Gly Phe

275

280

285

Val His Asp Val Ala Lys Ala His Phe Gly Gly Asp Phe Ser Gly His

290

295

300

Gln Ala Tyr Leu Cys Gly Pro Pro Ala Met Ile Asp Ala Cys Ile Thr

305

310

315

320

Thr Leu Met Gln Gly Arg Leu Phe Glu Arg Asp Ile Tyr His Glu Lys

325

330

335

Phe Ile Ser Ala Ala Asp Ala Gln Gln Thr Arg Ser Pro Leu Phe Arg

340

345

350

FIG. 9

Met Asp Ala Gly Arg Val Cys Gly Thr Val Thr Ile Ala Gln Thr Asp

5

10

15

Glu Arg Tyr Ala Cys Val Ser Gly Glu Ser Leu Leu Ala Gly Met Ala

20

25

30

Lys Leu Gly Arg Arg Gly Ile Pro Val Gly Cys Leu Asn Gly Gly Cys

35

40

45

Gly Val Cys Lys Val Arg Val Leu Arg Gly Ala Val Arg Lys Leu Gly

50

55

60

Pro Ile Ser Arg Ala His Val Ser Ala Glu Glu Glu Asn Asp Gly Tyr

65

70

75

80

Ala Leu Ala Cys Arg Val Val Pro Asp Gly Asp Val Glu Leu Glu Val

85

90

95

Ala Gly Arg Leu Arg Lys Pro Phe Phe Cys Gly Met Ala Cys Ala Gly

100

105

110

Thr Ala Ala Ile Asn Lys

115

FIG. 10

AGTCCGCCAT GGAGGCGACA CCGATCATGA ATCAGC 36

FIG. 11

CACCGACCAT GGATCAGCAC CCCACCGATC TTTC 34

FIG. 12


TGCCGCCTTC CATGGGTTCT GCCGCGAACA GCAG 34

FIG. 13

AGCAAGCCAT GGCCATCGAG CTGAAGACAG TCGACATCA 39

FIG. 14

CCGACCATCA CCTGCTCGGC CAGATGGAAG TCGAG 35

FIG. 15

COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
(Page 1)

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled DNA FRAGMENT CARRYING TOLUENE MONOOXYGENASE GENE, RECOMBINANT PLASMID, TRANSFORMED MICROORGANISM, METHOD FOR DEGRADING CHLORINATED ALIPHATIC HYDROCARBON COMPOUNDS AND AROMATIC COMPOUNDS, AND METHOD FOR ENVIRONMENTAL REMEDIATION, the specification of which ☒ is attached hereto ☐ was filed on _____ as United States Application No. or PCT International Application No. _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b), of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designates at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed

<u>Country</u>	<u>Application No.</u>	<u>Filed (Day, Mo, Yr.)</u>	<u>(Yes/No)</u> <u>Priority Claimed</u>
Japan	10-310801	30 October 1998	Yes

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or §365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112. I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application

<u>Application No.</u>	<u>Filed (Day, Mo, Yr.)</u>	<u>Status</u> <u>(Patented, Pending, Abandoned)</u>
------------------------	-----------------------------	--

I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number

FITZPATRICK, CELLA, HARPER & SCINTO
Customer Number: 05514

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon

Full Name of Sole or First Inventor Tetsuya Yano
Inventor's signature _____
Date _____ Citizen Subject of Japan
Residence 6-52-1101, Tsumada Higashi 1-chome, Atsugi-shi,
Kanagawa-ken, Japan
Post Office Address Canon Kabushiki Kaisha
30-2, Shimomaruko 3-chome, Ohta-ku, Tokyo, Japan

COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
(Page 2)

Full Name of Second Joint Inventor if any Tsuyoshi Nomoto

Second Inventor's signature _____

Date _____ Citizen Subject of Japan

Residence 2-5-102, Inogata 1-chome, Komae-shi, Tokyo, Japan

Post Office Address Canon Kabushiki Kaisha

30-2, Shimomaruko 3-chome, Ohta-ku, Tokyo, Japan

Full Name of Third Joint Inventor if any Takeshi Imamura

Third Inventor's signature _____

Date _____ Citizen Subject of Japan

Residence 5-23-101, Higashi Kaigan Kita 3-chome, Chigasaki-shi,

Kanagawa-ken, Japan

Post Office Address Canon Kabushiki Kaisha

30-2, Shimomaruko 3-chome, Ohta-ku, Tokyo, Japan

NY_MAIN 37496 v 1